



Medlive Technology Co., Ltd.
醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限責任公司)

Stock Code 股份代號 : 2192



INTERIM REPORT
中期報告 2023



Contents

目錄

Corporate Information 公司資料	2
Business Overview and Outlook 業務概覽及展望	4
Management Discussion and Analysis 管理層討論與分析	15
Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 未經審核中期簡明綜合損益及其他全面收益表	25
Unaudited Interim Condensed Consolidated Statement of Financial Position 未經審核中期簡明綜合財務狀況表	27
Unaudited Interim Condensed Consolidated Statement of Changes in Equity 未經審核中期簡明綜合權益變動表	29
Unaudited Interim Condensed Consolidated Statement of Cash Flows 未經審核中期簡明綜合現金流量表	30
Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註	33
Other Information 其他資料	56

Corporate Information 公司資料

BOARD OF DIRECTORS

Executive Directors

Ms. Tian Liping (*Chairwoman and Chief Executive Officer*)
Mr. Tian Lixin (*President*)
Mr. Tian Lijun
Ms. Zhou Xin

Non-Executive Directors

Mr. Eiji Tsuchiya
Dr. Li Zhuolin
(resigned with effect from 14 April 2023)
Mr. Kazutaka Kanairo
(appointed with effect from 14 April 2023)

Independent Non-Executive Directors

Mr. Richard Yeh
Dr. Ma Jun
Ms. Wang Shan

AUDIT COMMITTEE

Ms. Wang Shan (*Chairwoman*)
Mr. Richard Yeh
Dr. Ma Jun

NOMINATION COMMITTEE

Ms. Tian Liping (*Chairwoman*)
Mr. Richard Yeh
Dr. Ma Jun
Ms. Wang Shan

REMUNERATION COMMITTEE

Mr. Richard Yeh (*Chairman*)
Dr. Ma Jun
Ms. Wang Shan

JOINT COMPANY SECRETARIES

Ms. Yang Yanling
Ms. Szeto Kar Yee Cynthia (*ACG, HKACG*)
(resigned with effect from 12 June 2023)
Ms. Chu Cheuk Ting
(appointed with effect from 12 June 2023)

HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

REGISTERED OFFICE IN THE CAYMAN ISLANDS

PO Box 309
Ugland House
Grand Cayman
KY1-1104
Cayman Islands

董事會

執行董事

田立平女士 (*董事長及首席執行官*)
田立新先生 (*總裁*)
田立軍先生
周欣女士

非執行董事

樋屋英二先生
李卓霖博士
(其辭任於2023年4月14日生效)
金色一賢先生
(其委任於2023年4月14日生效)

獨立非執行董事

葉霖先生
馬軍醫師
王珊女士

審核委員會

王珊女士 (*主席*)
葉霖先生
馬軍醫師

提名委員會

田立平女士 (*主席*)
葉霖先生
馬軍醫師
王珊女士

薪酬委員會

葉霖先生 (*主席*)
馬軍醫師
王珊女士

聯席公司秘書

楊艷玲女士
司徒嘉怡女士 (*ACG · HKACG*)
(其辭任於2023年6月12日生效)
朱卓婷女士
(其委任於2023年6月12日生效)

香港證券登記處

卓佳證券登記有限公司
香港
夏慤道16號
遠東金融中心17樓

開曼群島註冊辦事處

PO Box 309
Ugland House
Grand Cayman
KY1-1104
Cayman Islands

AUTHORIZED REPRESENTATIVES

Mr. Tian Lijun
Ms. Szeto Kar Yee Cynthia
(resigned with effect from 12 June 2023)
Ms. Chu Cheuk Ting
(appointed with effect from 12 June 2023)

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

COMPANY'S WEBSITE

www.medlive.cn

STOCK CODE

2192

HEADQUARTERS IN THE PRC

E1
Red Manor International Bonded Innovation Park
No. 1 Baijialou Chaoyang North Road
Chaoyang District, Beijing
PRC

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman KY1-1102
Cayman Islands

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

31/F., Tower Two, Times Square
1 Matheson Street
Hong Kong

PRINCIPAL BANKS

Bank of Beijing Co., Ltd.
The Industrial Bank Co., Ltd.
China CITIC Bank Corporation Limited
DBS Bank (China) Limited
China CITIC Bank International Limited
DBS Bank (Hong Kong) Limited
Ping An Bank Co., Ltd.
Bank of China (Hong Kong) Limited
China Merchants Bank Co., Ltd.

授權代表

田立軍先生
司徒嘉怡女士
(其辭任於2023年6月12日生效)
朱卓婷女士
(其委任於2023年6月12日生效)

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

公司網站

www.medlive.cn

股份代號

2192

中國總部

中國
北京朝陽區
朝陽北路白家樓甲1號
紅莊國際文化保稅創新園E1

開曼群島股份登記及過戶總處

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman KY1-1102
Cayman Islands

香港主要營業地點

香港
勿地臣街1號
時代廣場二座31樓

主要往來銀行

北京銀行股份有限公司
興業銀行股份有限公司
中信銀行股份有限公司
星展銀行(中國)有限公司
中信銀行(國際)有限公司
星展銀行(香港)有限公司
平安銀行股份有限公司
中國銀行(香港)有限公司
招商銀行股份有限公司

Business Overview and Outlook 業務概覽及展望

BUSINESS REVIEW

In early 2023, as hospitals resumed regular diagnosis and treatments after the pandemic and the approval process for new drugs sped up, digital marketing of the pharmaceutical industry witnessed a rebound. Faced with policies with focus on optimizing medical insurance expenditures, decentralizing medical resources, and combating corruption in healthcare industry, pharmaceutical and medical device companies proactively pursued digitalization and intelligent transformation and upgrades. This has led them to continually explore more efficient and precise digital marketing models, which in turn has driven rapid growth in the digital marketing of the pharmaceutical sector.

As the leading online professional physician platform in China, the Group has focused on using technology to support physicians' clinical decision making for over 20 years. Our self-developed *Medlive* platform is widely recognized by physicians and other medical professionals in China and has become the most popular professional medical platform. As of 30 June 2023, the number of registered users through our website, desktop application and mobile application was approximately 6.4 million, approximately 3.81 million of whom were licensed physicians in China, representing approximately 86.6% of the total number of licensed physicians in China as of the same date.

With its high-quality professional medical content and rich medical tools, our *Medlive* platform meets the three major needs of physicians in clinical diagnosis, professional learning and medical research, and is embedded in the daily work of many physicians in China. In the first half of 2023, the average MAUs (without duplication) of the *Medlive* platform reached 2.20 million. With a higher coverage rate among Chinese physician users and relatively higher MAUs on our platform, we have a solid foundation for developing precision marketing solutions.

In June 2023, we acquired 50% equity interest in Beijing SCMedcon Co., Ltd.* (北京石成醫學諮詢有限公司) (“SCMedcon”), further expanding the scope and coverage of our service offerings to the pharmaceutical and medical device companies. SCMedcon is committed to developing a healthcare ecosystem encompassing clinical institutions, clinical experts, diverse R&D institutions, patient organizations, and government regulatory bodies. Its mission is to empower pharmaceutical and medical device companies to enhance their market recognitions and foster medical dialogue and collaboration. “CMAC” is

業務回顧

2023年初，伴隨疫情後醫院端診療恢復常態及新藥獲批進程加速，醫藥數字營銷行業也實現了復甦。面對節約醫保開支、醫藥資源下沉、醫療行業反腐的政策大趨勢，製藥及醫療設備公司積極尋求數字化、智能化轉型升級，不斷探索更高效更精準的數字化營銷模式，醫藥數字營銷行業應勢快速發展。

本集團作為中國領先的在線專業醫師平台，二十多年來，致力於以科技創新助力醫師作出更好的臨床決策。我們自主研發的醫脈通平台獲得中國醫師及其他醫療專業人士的廣泛認可，已成為最受歡迎的專業醫療平台。截至2023年6月30日，通過我們的網站、桌面應用程序及移動應用程序註冊的用戶數量約6.4百萬名，其中約3.81百萬名用戶為中國執業醫師，佔截至同日中國執業醫師總數約86.6%。

我們的醫脈通平台憑藉高質量的專業醫學內容和豐富的醫學工具，滿足醫師在臨床診療、專業學習以及醫學研究的三大需求，嵌入到了眾多中國醫師日常的工作流程中。於2023年上半年，醫脈通平台去重過後的每月平均活躍用戶數達到2.20百萬人。我們平台較高的中國醫師用戶覆蓋率和用戶活躍度，為我們開展精準營銷服務提供了堅實的基礎。

2023年6月，我們收購了北京石成醫學諮詢有限公司（「石成醫學」）50%股權，進一步拓展本集團面向製藥及醫療設備公司服務的深度和廣度。石成醫學致力於構建包括臨床機構、臨床專家、各類研發機構、患者組織、政府監管部門在內的醫療行業生態系統，助力中國藥械企業提升行業認知，促進醫學交流與合作。CMAC是石成醫學自創的品牌，每年有超過1,500名演講嘉賓和6,000多名業內專業

a brand established by SCMedcon. Every year, over 1,500 speakers and over 6,000 experts in the industry participated in conferences held under the “CMAC” brand. In recent years, China Innovative Medicine (Device) Medical Conference and CMAC Annual Meeting has witnessed profound development, driving high-quality advancements in domestic medical affairs and drug research. SCMedcon has already established strategic cooperation with various pharmaceutical and medical device companies and medical industry associations. Our cooperation with SCMedcon is conducive to enhancing the quality and influence of the healthcare ecosystem for the provision of upstream and downstream integrated solutions for the medical industry.

Since the inception of the Group, we have proactively pursued technological innovation, with a strong emphasis on the seamless integration of technology and healthcare. We are committed to applying advanced technologies to various scenarios that physicians need in their daily work, such as diagnosis, medication, ward rounds, medical conferences, medical knowledge retrieval, research writing, patient management and education. We provide physicians with comprehensive clinical decision-making support, effectively solve clinical and scientific research problems faced by physicians, and help them improve work efficiency. In the first half of 2023, we continued to invest in artificial intelligence (“AI”) technology. We have fostered collaborations with various GPT model platforms at home and abroad to introduce commercial products and services enhanced by the GPT framework. We will further promote digitalization, with focus on refining content creation efficiency on our platform and enhancing intelligent user engagement, in order to deliver more diversified and efficient digital precision marketing solutions tailored for pharmaceutical and medical device companies. Moreover, we have proactively built a vertical model based on the needs of the Group’s business development. By embedding the expertise and experience from the medical sector into the model, we aim to provide the medical field with more intelligent services.

The Group generates revenue by offering three categories of solutions to address various needs of its *Medlive* platform participants, namely, precision marketing and corporate solutions, medical knowledge solutions and intelligent patient management solutions. For the six months ended 30 June 2023, the Group’s revenue was approximately RMB173.5 million, representing an increase of 31.5% as compared with the same period last year. While expanding revenue, the Group continuously enhanced its profitability. The Group’s net profit

人士參與CMAC會議。近年來，中國創新藥物(械)醫學大會暨CMAC年會迅猛發展，推動了國內醫學事務和新藥研發的高質量發展。目前，石成醫學已與眾多製藥及醫療設備公司、醫療行業協會達成戰略合作。我們與石成醫學的合作將有利於提升醫療行業生態系統的品質和影響力，為醫藥行業上下游提供更全面的解決方案。

本集團自成立以來，積極擁抱技術創新，高度重視科技與醫學的有機融合。我們致力於將前沿科技應用於醫師日常工作所需的眾多場景，如診斷、用藥、查房、醫學會議、醫學檢索、論文寫作、患者管理與教育等，為醫師提供了全流程決策支持，切實解決醫師面臨的臨床與科研問題，幫助醫師提升工作效率。2023年上半年，我們繼續在人工智能(AI)領域持續投入。我們陸續與國內外眾多GPT模型平台合作，第一時間實現基於GPT模型的商業產品與服務應用。我們將進一步加強數字化能力，特別是在提升平台內容生產效率和用戶智能交互等方面，持續為製藥及醫療設備公司客戶提供更豐富、更高效的數字化精準營銷解決方案。此外，我們積極自建貼合本集團業務發展的垂直領域大模型，將醫療行業的專業知識和經驗融入大模型的訓練，力爭以更智能的服務為醫療行業賦能。

本集團通過提供三大解決方案滿足醫脈通平台參與者的不同需求從而獲得收入，即精準營銷及企業解決方案、醫學知識解決方案及智能患者管理解決方案。截至2023年6月30日止六個月，本集團的收入約人民幣173.5百萬元，較去年同期增長31.5%。本集團在拓展收入的同時不斷提升盈利能力，本集團的淨利潤由截至2022年6月30日止六個月的人

Business Overview and Outlook 業務概覽及展望

increased by 267.5% from RMB27.7 million for the six months ended 30 June 2022 to RMB101.7 million for the six months ended 30 June 2023. The net profit margin increased from approximately 21.0% for the six months ended 30 June 2022 to approximately 58.6% for the six months ended 30 June 2023, representing an increase of 37.6 percentage points. The adjusted net profit for the six months ended 30 June 2023 was approximately RMB119.8 million, representing an increase of approximately 122.0% as compared with approximately RMB54.0 million for the six months ended 30 June 2022. The adjusted net profit margin for the six months ended 30 June 2023 was approximately 69.0%, representing an increase of 28.1 percentage points as compared with approximately 40.9% for the six months ended 30 June 2022.

Precision marketing and corporate solutions

The majority of the Group's revenue comes from precision marketing solutions, which provide digital medical marketing services to pharmaceutical and medical device companies. Attributable to the post-pandemic resumption of regular diagnosis and treatments at hospitals, paired with the expedited approval process for new drugs, the product sales and marketing activities of pharmaceutical and medical device companies have regained momentum rapidly. In response to the market needs, the precision marketing and corporate solutions provided by the Group empowered our customers to maintain consistent engagement of physicians throughout the whole lifecycle of pharmaceutical and medical devices and provide compliant, precise and effective academic training for physicians, and have been widely recognized by customers in the industry. In the first half of 2023, the number of customers of these solutions was 124, increased by 40 as compared with 84 in the first half of 2022. At the same time, the number of products covered increased steadily from 181 in the first half of 2022 to 253 in the first half of 2023. For the six months ended 30 June 2023, the revenue of the Group's precision marketing and corporate solutions increased by 33.5% from the same period last year to RMB158.1 million.

We conduct thorough analysis of the academic features and life cycle of pharmaceutical and medical device products, and provide effective and results-oriented precision digital marketing services. Our digital precision marketing services offer solutions covering the whole process including the research and formulation of medical strategy, analysis of learning profile for experts and specialists, digital editing of educational content, event design and execution, precise distribution of digital

人民幣27.7百萬元增加至截至2023年6月30日止六個月的人民幣101.7百萬元，同比增長267.5%。淨利潤率由截至2022年6月30日止六個月的約21.0%增加37.6個百分點至截至2023年6月30日止六個月的約58.6%。截至2023年6月30日止六個月的經調整淨利潤約人民幣119.8百萬元，較截至2022年6月30日止六個月約人民幣54.0百萬元增加約122.0%。截至2023年6月30日止六個月的經調整淨利潤率約69.0%，較截至2022年6月30日止六個月的約40.9%增加28.1個百分點。

精準營銷及企業解決方案

本集團大部分營業收入來自精準營銷解決方案，該解決方案為製藥及醫療設備公司提供數字醫療營銷服務。受益於疫情後醫院端診療恢復常態及新藥獲批進程加速，製藥及醫療設備公司客戶的產品銷售和市場推廣工作加速恢復。本集團提供的精準營銷及企業解決方案順應市場需求，助力客戶實現圍繞藥械產品全生命週期的醫師覆蓋，合規、精準、高效地進行醫師學術教育，獲得了製藥及醫療設備公司客戶的廣泛認可。於2023年上半年，該解決方案所覆蓋的客戶數量為124家，較2022年上半年的84家增加了40家。同時，覆蓋的產品數量穩步提升，由2022年上半年的181種提升至2023年上半年的253種。截至2023年6月30日止六個月，本集團精準營銷及企業解決方案的收入較去年同期增長33.5%至人民幣158.1百萬元。

我們充分分析藥械產品的學術特點，以及所處的生命週期，提供以效果為導向的精準數字營銷服務。精準數字營銷服務包含醫學策略調研及制定，專家及專科醫生學習畫像分析，數字化教育內容編輯，活動設計及執行，數字化教育內容精準傳播，效果評估等全流程解決方案。我們建立醫脈通全渠道互聯網生態，

educational content and evaluation of results. We establish a fully integrated internet ecosystem through *Medlive*, connecting all channels including websites, mobile APPs, social media accounts, online communities and electronic newsletters. We build a database system that encompasses massive amount of data on browsing behavior of physicians, forming rich digital behavior and cognitive profiles of physicians. Our disease knowledge base platform is a content aggregation platform as well as a personal behavior data platform for physicians. Starting from this platform, we can radiate to various scenarios including clinical research, information browsing, guideline learning, case discussion, patient education, internet diagnosis and treatment and academic conferences. Based on comprehensive and rich insights into physicians, we use AI technology to establish an analysis and content recommendation engine for physicians' online learning. The model not only meets their personalized learning needs for clinical knowledge and experience, but also effectively support the digital education of clinical physicians throughout the entire lifecycle of pharmaceutical and medical device products in core, intermediate and basic markets. This empowers the pharmaceutical and medical device companies to selectively and precisely deliver content to targeted physicians at their preferred times and through their preferred channels.

We charge the pharmaceutical and medical device companies based on the number of clicks on their paid content engaged by targeted physicians. The scale of collaboration with existing customers further expands as the number of customers and products using our solutions continue to increase. In the first half of 2023, the number of paid clicks was 4.27 million, representing an increase of 34.3% as compared with the same period last year.

We also offer various corporate solutions that enable (i) pharmaceutical and medical device companies to cost-effectively conduct market research; and (ii) pharmaceutical and medical device companies, hospitals and other stakeholders of the healthcare industry to improve the efficiency of clinical trials and medical research. In the first half of the year, we leveraged the brand image of the *Medlive* platform in the clinical research field, as well as the close collaboration with pharmaceutical and medical device companies before and after product launch, to develop real-world studies (“RWS”), trial design and protocol writing, medical monitoring and article support, data management and statistics and scientific research services for physicians, and have achieved satisfactory progress in the fields of oncology, hematology, neurology, pediatrics and cardiovascular.

將網站、移動APP、社交媒體公眾號、線上社群、電子週刊等全渠道打通，建立囊括海量醫生閱覽行為數據的數倉系統，形成了豐富的醫生數字化行為畫像和認知畫像。我們構建的疾病知識庫中台，既包含了內容聚合平台，也包含醫生個人行為數據庫平台。以該中台出發，可以輻射醫生臨床研究、資訊閱覽、指南學習、病例研討、患者教育、互聯網診療、及參加學術會議等多個場景。基於對醫生全面且豐富的洞察，我們利用AI技術建立醫生線上學習的分析及內容推薦引擎，該模型在滿足醫生個性化臨床知識及經驗學習需求的同時，也有效地支持藥械產品全生命週期在核心市場，腰部及基層市場落地實施臨床醫生的數字化教育，幫助製藥及醫療設備公司客戶篩選目標醫生，並在該目標醫生偏好的渠道和時間，精準向醫生推送內容。

我們按照目標醫生點擊客戶付費推送內容的次數，向製藥及醫療設備公司收費。憑藉該解決方案服務的客戶及產品數量不斷增加，與現有客戶的合作規模不斷擴大。於2023年上半年，我們獲得的付費點擊次數為4.27百萬次，較去年同期上升34.3%。

我們亦提供多種企業解決方案，(i)讓製藥及醫療設備公司以具備成本效益的方式進行市場研究；及(ii)幫助製藥及醫療設備公司、醫院及醫療行業的其他參與者提升臨床試驗及醫學研究的效率。今年上半年，我們發揮醫脈通平台在臨床科研領域的品牌效應，以及同藥械企業的上市後及上市前團隊的密切合作基礎，繼續開拓真實世界研究(「RWS」)、試驗設計和方案撰寫服務、醫學監查和文章支持服務、數據管理和統計以及醫生科研服務，並在腫瘤、血液、神經、兒科、心血管等領域取得令人滿意的進展。

Business Overview and Outlook 業務概覽及展望

As the clinical problems to be addressed by RWS become increasingly complex, the clinical scenarios become more diverse and the quality requirement for data becomes higher, we rely on our team's rich experience in the clinical research industry, solid medical and statistical capabilities, and collaborate with pharmaceutical and medical device companies to provide customized trial design. We also provide patient follow-up process, data collection process, monitoring and medical review process design for each project based on the indications and the characteristics of research centers and patients, greatly improving the efficiency and pace of the trials. In addition, we combine RWS delivery with digital marketing, effectively integrating evidence generation from RWS with evidence-based digital marketing.

In the first half of 2023, we established the Medlive Oncology Clinical Science Committee (醫脈通腫瘤臨床科學委員會). The committee gathers top-tier experts from various fields, such as gastrointestinal cancer, hematological malignancies, urological cancer, melanoma, lung cancer, breast cancer, and gynecological cancer. Building upon the extensive collaborations established between the Group and pharmaceutical enterprises, the committee reinforces our business foundation in areas including clinical research of oncology drugs guided by clinical science, clinical development strategies for innovative drugs, clinical science advisory boards, medical monitoring, training for clinical development, and cultivation of medical professionals.

Medical knowledge solutions

The Group's medical knowledge solutions satisfy the needs of physicians for continuing medical education and clinical decision support and the needs of other healthcare professionals for professional medical information. The Group's medical knowledge solutions deliver medical knowledge content through multiple user-friendly channels, including its website, mobile applications, desktop applications, WeChat mini-programs and WeChat official accounts. On the back of its cancer disease knowledge database, the Group expanded its clinical decision support products to cover other diseases and areas such as cardiovascular, endocrine, vestibular medicine, neurological infectious, mental, respiratory, digestive, obstetrics and pediatrics diseases. These coupled with the other clinical guides and clinical drug reference tools offered by the Group provide physicians with a more comprehensive clinical decision support tool at the point of care, helping them to give diagnosis and treatment in an effective and efficient manner.

面對RWS要解決的臨床問題越來越複雜，臨床場景越來越多樣，數據質量要求越來越高，我們依託團隊豐富的臨床研究行業經驗，扎實的醫學和統計能力，配合醫學和藥械企業的醫學策略，提供定製化的試驗設計。同時根據項目的適應症、研究中心和患者的特點，在每個項目提供定製化的患者隨訪流程、數據採集流程、監查和醫學審核流程設計，極大的提升了試驗的效率和速度。此外，我們將RWS交付與數字營銷結合，將RWS的證據生成與基於證據的數字營銷有效結合。

2023年上半年，我們發起成立了醫脈通腫瘤臨床科學委員會。該委員會聚集了消化腫瘤、血液腫瘤、泌尿腫瘤、黑色素瘤、肺癌、乳腺癌、婦瘤等領域的頂尖專家，結合本集團與製藥企業已經建立的廣泛合作，為我們提供以臨床科學為導向的抗腫瘤藥臨床研究、創新藥臨床開發策略、臨床科學顧問會、醫學監查、臨床開發培訓和醫學人員培養等業務打下堅實基礎。

醫學知識解決方案

本集團的醫學知識解決方案可滿足醫師對持續醫學教育及臨床決策支持的需求及醫療專業人員對專業醫學信息的需求。我們的醫學知識解決方案通過多個簡便的渠道提供醫學知識內容，包括我們的網站、移動應用程序、桌面應用程序、微信小程序及微信公眾號。依託癌症疾病知識數據庫，我們將臨床決策支持產品擴展至心血管、內分泌、前庭醫學、神經感染、精神、呼吸、消化、婦產及兒科等其他疾病及領域。以上舉措與我們提供的其他臨床指南及臨床用藥參考工具相結合，為醫師提供診療方面更加全面的臨床決策支持工具，幫助醫師以有效且高效的方式作出診斷及治療等方面的決策。

To further enhance our service quality and gain a deeper understanding of the needs of physicians, we issued the first report of the Survey on Digital Life of Clinical Physicians in China (《中國臨床醫生數字生活調研》) in the first half of 2023. The survey collected data from 8,597 clinical physicians, covering more than 50 departments across 31 provincial administrative regions in mainland China. Apart from providing a comprehensive analysis of the online medical behaviors of Chinese clinical physicians, the report also conducts study of related digital platform services and features. By identifying the current challenges faced in areas such as clinical research, learning, diagnosis, and patient management, the insights from this report enable us to refine our academic information services for clinical physicians.

In the first half of 2023, the Group further consolidated our platform advantage by continuously enriching the professional medical content on our *Medlive* platform to increase the coverage and engagement of physician users. In the first half of the year, the *Medlive Knowledge Base* added disease coverage for 4 more departments, with the number of disease entries exceeding 965. Our video platform, *eBroadcasting*, added approximately 11,000 new videos, bringing the total number of videos to over 59,000. In terms of clinical guidelines, we have reinforced the strategic cooperation with the Chinese Medical Association, Wanfang Medical Database and NCCN (National Comprehensive Cancer Network of the United States). The number of clinical guidelines on our *Medlive* platform increased to 26,000.

In order to better enhance the scientific research capability of Chinese physicians, we continue to step up our strategic layout in the field of scientific research and accelerate the deployment of “scientific research efficiency enhancement” products, in order to allow digital technology to better assist clinical research. Last year, we launched the *eClinicalResearch* platform, aiming to support physicians’ scientific research to be more efficient through technology, continuously expand the service model for physicians and improve the service level of the platform. In the first half of the year, we upgraded the *eMedical Papers Service* platform, introducing the SCI manuscript submission feature with intelligent journal selection services specially designed for physicians aiming to publish their research findings in core journals. Leveraging the strengths of AI technologies, our platform empowers physicians to select the most suitable journals, thus increasing the success rate of publication and overcoming the challenges of journal selection and submission.

為進一步提升服務質量，深入挖掘醫生用戶需求，於2023年上半年，我們推出了首期《中國臨床醫生數字生活調研》報告，該報告共收集了8,597條臨床醫生調研樣本數據，覆蓋了中國大陸31個省級行政區的50多個科室種類。該報告不僅從多維度深入分析了中國臨床醫生線上的醫學行為，還就相關的數字化平台服務和功能做了延展探索，通過對當前臨床醫生科研、學習、診療、患者管理等方面痛點的挖掘，以指導我們更好地進行臨床醫生的學術信息服務工作。

2023年上半年，本集團繼續通過豐富醫脈通平台的專業醫學內容，進一步夯實平台優勢，以提升醫師用戶的覆蓋度與活躍度。今年上半年，我們的「醫知源」疾病知識庫新增4個科室的疾病覆蓋，詞條數量超過965篇。我們的視頻頻道「e脈播」新增約1.1萬條視頻，總視頻數量提升至5.9萬條以上。臨床指南方面，我們加強與中華醫學會、萬方醫學數據庫、NCCN(美國國家綜合癌症網絡)的戰略合作，將醫脈通平台上的臨床指南數量提升至2.6萬篇。

為了更好助力中國醫生科研水平的提升，我們繼續加緊科研領域戰略佈局，加快「科研效率提升」型產品部署，讓數字化技術更好地輔助臨床科研。去年我們推出「e研通」平台，旨在通過技術提升醫生科研效率，不斷拓寬面向醫生的服務模式，提升平台服務水平。今年上半年，我們又升級了「論文通」平台，並針對醫生在核心期刊發表科研成果的需求，推出了SCI投稿智能選刊服務，充分發揮AI技術優勢，幫助醫生精準匹配期刊，提高發表成功率，解決醫生選刊投稿難題。

Business Overview and Outlook 業務概覽及展望

In 2022, the Group entered into cooperation with the National Health Commission's Capacity Building and Continuing Education Center for the initiative of Enhancing Precision Capabilities for Oncology Departments in County Medical Institutions in China (《中國縣域醫療機構腫瘤專科精準能力提升》). In the first half of 2023, we conducted research to understand the specific needs and current conditions of oncologists across county-level institutions. Through the research, we gained insights into the establishment of oncology departments, talent development, prevalent tumor types, available treatment options, and the requirements for ongoing education and training in these regions. Based on the findings, we co-published the Research Report on the State of Oncology Diagnosis and Treatment in County Areas of China (《中國縣域腫瘤診療現狀調研報告》).

Intelligent patient management solutions

The Group's intelligent patient management solutions offer comprehensive chronic disease management services, including (i) diseases knowledge dissemination and treatment compliance monitoring management services to patients through Internet hospital; and (ii) condition-specific patient education services in collaboration with non-profit organizations. The Group's Internet hospital-based chronic disease management currently focuses on breast cancer, lung cancer, ovarian cancer, Parkinson's, lymphoma, stroke and diabetes management and will gradually expand to other chronic diseases in the future. As at 30 June 2023, the Group's chronic disease management services platform had accumulated approximately 311,000 users and in addition approximately 89,000 participating physicians.

In the first half 2023, to further enhance patients' satisfaction with online consultations and address the challenges of limited high-end medical resources, our Internet hospital launched the “醫知行” expert video consultation platform. This platform congregates numerous clinical experts with deputy chief titles or above from China's top 100 hospitals. Through video consultations, we aim to closely replicate the experience of an in-person hospital visit, thus enhancing the overall user experience for healthcare consultation. Users can easily browse and select from a roster of qualified physicians on the platform, ensuring they can obtain reliable and timely responses to their health concerns.

2022年，本集團與國家衛生健康委能力建設和繼續教育中心達成合作，雙方計劃在《中國縣域醫療機構腫瘤專科精準能力提升》項目展開合作，2023年上半年雙方通過開展縣域腫瘤醫生的實際需求與現狀調研，完成了對縣域腫瘤專科的科室建設、人才培養、以及常見多發的腫瘤清單、目前已有的治療手段以及對繼續教培訓的需求等情況的了解，並共同發佈《中國縣域腫瘤診療現狀調研報告》。

智能患者管理解決方案

本集團的智能患者管理解決方案提供全面的慢性疾病管理服務，包括(i)通過互聯網醫院提供患者疾病科普及治療依從性監控的管理服務；及(ii)與非盈利機構合作針對特定病情的患者教育服務。本集團以互聯網醫院為基礎的慢性病管理目前專注於乳腺癌、肺癌、卵巢癌、帕金森、淋巴瘤、卒中及糖尿病管理，日後亦將會逐步擴展至其他慢性疾病。截至2023年6月30日，本集團慢性疾病管理服務平台已累積約31.1萬名用戶，另外參與醫師約8.9萬名。

2023年上半年，為了進一步提升患者對線上問診的滿意度，解決高端醫療資源匱乏的難題，我們的互聯網醫院正式推出「醫知行」專家視頻諮詢平台。該平台上匯集了眾多全國百強醫院副高級別以上的臨床專家，以視頻諮詢形式最大程度還原患者在醫院問診的場景，提升用戶健康諮詢體驗。用戶可在平台醫生列表裡篩選符合自己需求的醫生，及時便捷地獲取健康問題的權威解答。

BUSINESS OUTLOOK

In the future, the Group will continue its efforts to further solidify its position as the leading online professional physician platform in China by pursuing the following strategies:

- We will continue to enrich the professional medical content and product tools on our *Medlive* platform to further increase the penetration and participation of physicians. We will continue to use our insights into data to improve the accuracy and relevance of personalized content recommendations and search results. We also plan to expand the sources of content generation and provide customized medical content for physicians working in county-level areas and community hospitals. In addition, we will continue to strengthen our strategic cooperation with the Chinese Society of Clinical Oncology (“**CSCO**”). We plan to collaborate with CSCO for the provision of comprehensive support for clinical research of new anti-cancer drugs, continuous education of physicians and staff of pharmaceutical and medical device companies, patient education, publication and media and conference services.
- We will continue to establish the Group’s technological platform and expand its application scope. AI and machine learning have tremendous potential in the healthcare industry. We plan to increase our efforts in technology development, combining exploration of AI technology with our business to drive development, including using unique proprietary database to continuously develop innovative research tools featuring AI technology, such as AI writing assistants, to solve the efficiency dilemma for physicians in research topic selection. We will continue to establish a knowledge graph and further optimize the search and recommendation function of the 醫搜 platform through semantic and contextual links. AI technology will be fully utilized for expanding the coverage of *Medlive Knowledge Base* in respect of diseases to provide more concise and effective knowledge services for primary care physicians. We will continue to improve and enrich the *eClinicalResearch* platform, empowering physicians with digital technology to improve research efficiency. In addition, we will continue to invest in the development of AI large models in vertical aspects. During the training of these large models, we will integrate our extensive industry experience and specialized medical knowledge gained from serving pharmaceutical and medical device companies. Continuous enhancement of the prediction accuracy and response speed of the large models will also be carried out.

業務展望

未來，本集團將通過以下策略進一步鞏固其中國領先在線專業醫師平台的地位：

- 持續豐富本集團醫脈通平台上的專業醫學內容及產品工具，進一步增加醫師的滲透率及參與度。我們將繼續利用對數據的洞察力來提高個性化內容推薦及搜索結果的準確性及相關性。我們亦計劃進一步擴大內容生成的來源並為在縣級地域及社區醫院工作的醫師提供量身定製的醫學內容。此外，我們將繼續加強與中國臨床腫瘤學會（「**CSCO**」）的戰略合作，計劃與CSCO共同在抗癌新藥臨床研究支持、醫師、製藥及醫療器械公司人員的持續教育、患者教育、出版支持以及媒體和會議服務領域為醫師及其他人士提供全面支持。
- 繼續建設本集團的技術平台及擴展應用範圍。人工智能和機器學習在醫療行業有著巨大的發展潛力，我們計劃繼續加大技術開發力度，將AI技術領域的探索與業務有機結合，推動業務發展，包括利用獨特專有的數據庫持續開發配備AI技術的工具，如AI寫作助手等創新性科研工具，解決醫生在科研選題思路上的效率困境。我們將繼續建立知識圖譜，通過語義及上下文鏈接進一步優化「醫搜」平台的搜索及推薦功能。我們將充分利用AI技術拓展「醫知源」的疾病覆蓋範圍，為基層醫生提供更加簡潔、有效的知識服務，不斷完善與豐富「e研通」平台，以數字化技術賦能醫生科研效率的提升。此外，我們將繼續投入垂直領域AI大模型的開發，在大模型訓練時融入我們長期服務藥械企業的行業經驗及專業醫學知識，不斷增強大模型的預測精度和響應速度。

Business Overview and Outlook 業務概覽及展望

- We will expand the Group's customer network and continuously develop solutions that meet customer development needs. In the future, we will closely follow the trend of digital transformation of pharmaceutical and medical device companies and continue to leverage the unique advantages of our online professional physician platform. We will further expand our coverage of physician users and pharmaceutical and medical device companies, strengthen our dual-driven business model, and facilitate the growth of our precision marketing and corporate solution business. In particular, in the field of new special drugs and medical devices, we will further leverage the advantages of the *Medlive* platform in supporting clinical research of physicians, integrate academic resources from various associations and academic leaders in various specialty fields, and capitalize on our platform's extensive physicians resources to help pharmaceutical and medical device companies promote professional academic content to target hospitals and department physicians in both core markets and the vast primary market through a precise education system. As such, it will enable customers to penetrate the Chinese market rapidly. Efforts will be made to enhance customer loyalty through high-quality service levels, attracting more digital marketing expenditure from pharmaceutical and medical device companies. To this end, we will continue to invest in developing comprehensive solutions which comprise medical strategy, market strategy and multi-channel digital strategy. We will also add new functions to existing solutions, including designing digital marketing solutions that meet the product characteristics of oncology drugs, chronic disease drugs, rare disease drugs, over-the-counter medicines and medical devices.
- 擴展本集團的客戶網絡並持續開發順應客戶發展需求的解決方案。未來，我們將緊抓藥械企業數字化轉型的大趨勢，繼續發揮在線專業醫師平台的獨特優勢，持續拓展對醫師用戶及藥械企業客戶的覆蓋，加強雙輪驅動的商業模式，推動精準營銷及企業解決方案業務的增長。特別是在新特藥及醫療器械領域，進一步發揮醫脈通平台在支持醫生臨床科研方面的優勢，通過整合各類學會及各專科領域學術帶頭人的學術資源和我們平台廣大的醫師資源，通過精準教育系統，助力藥械企業實現從核心市場到廣闊基層市場的目標醫院、目標科室醫生的專業學術內容推廣，幫助客戶快速覆蓋中國市場。我們將以高質量的服務水平提升客戶黏性，吸納更多藥械企業客戶的數字推廣營銷開支。為實現相關目標，我們將繼續投資開發包括醫學策略、市場策略、數字化多渠道策略的全方位的解決方案，以及為現有解決方案添加新功能，包括為腫瘤藥品、慢病藥品、罕見病藥品、非處方藥品及醫療設備產品設計滿足產品特點的數字營銷解決方案。

- We will continuously expand the service offerings of the Group, further extend the depth and breadth of clinical research services, provide more extensive support to pharmaceutical and medical device companies in accumulating evidence through RWS, and support clinical decision-making and marketing. Leveraging the advantages of the *Medlive* platform and clinical experts, we will further consolidate our unique clinical science services to provide scientific and advanced research strategy support for clinical research. Based on the Group's overseas advantages, we will actively expand the implementation of overseas clinical trials and the establishment of overseas clinical science advisory boards. In collaboration with a member of the Group, SCMedcon, we will launch clinical research training programs aimed at benefiting clinical researchers and practitioners in the fields of clinical research of pharmaceuticals and medical devices. At the same time, we will further optimize the DCT platform, as we believe that in the future, with the increasing demand for remote and intelligent clinical trials, a localized DCT platform that meets the needs of Chinese physicians and patients will be more widely used in clinical trials. Meanwhile, we continue to leverage our model of recruiting trial participants based on a vast network of physicians and patients. On one hand, leveraging our proprietary physician database and an AI model, we match physicians with recruitment projects to obtain targeted participants more precisely. On the other hand, we use natural language processing (“NLP”) technology for structured processing of medical cases, combined with AI follow-up templates to record and analyze communication details, and establish patient profiles. This achieves precise matching between physicians, projects and patients in both directions, applying the advantages of digitalization to clinical patient recruitment. In addition, our integrated medical services include digital patient community management, patient management based on internet hospitals, patient call centers, patient self-management tools, patient education knowledge bases, patient assistance services as well as physician-patient and patient-patient interaction tools. Together with products such as patient surveys design, we form a “patient-oriented” integrated medical service that supports the full life cycle of drugs.
- 持續拓展本集團服務品項，進一步擴展臨床研究服務的深度和廣度，更廣泛支持藥械企業通過RWS不斷拓展循證證據的積累，支持臨床決策和市場營銷。依託醫脈通平台和臨床專家的優勢，繼續強化我們獨有的臨床科學服務，為臨床研究提供科學、先進的研究策略支持。依託本集團海外優勢積極拓展海外臨床試驗實施、海外臨床科學顧問會的開展。與集團內石成醫學攜手推出惠及臨床研究者和藥械臨床研究從業者的臨床研究培訓。同時，進一步優化DCT平台，因為我們相信未來隨著臨床試驗遠程化和智能化需求的提升，符合中國醫師和患者需求的本土化DCT平台將更廣泛的在試驗中應用。同時，持續發揮基於全網海量醫生資源的醫帶患的受試者招募模式。一方面基於我們平台自有的醫師畫像，搭配AI模型將醫生與招募項目進行匹配，更精準地獲取目標受試者；另一方面，使用自然語言處理([NLP])技術進行病例結構化處理，再配合AI跟進模版進行溝通詳情記錄與分析，建立患者畫像，雙向實現醫師與項目與患者間的精準匹配，將數字化的優勢應用在臨床患者招募。此外，我們的醫患一體化服務包含了數字化患者社群管理、基於互聯網醫院的患者管理、患者呼叫中心、患者自我管理工具、患者教育知識庫、患者援助服務、醫患及患間互動工具，研究設計患者調研等產品，形成了支持藥品全生命週期的「以患者為中心」的醫患一體化服務。

Business Overview and Outlook 業務概覽及展望

- Explore strategic partnerships and integrate industry resources through investments and acquisitions. Leveraging our proprietary platform of professional physicians, we aim to expand strategic collaborations with domestic and overseas authoritative institutions on the footing of our existing business. In July of this year, we established a profound strategic cooperation with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration. This collaboration will capitalize on the policy advantages of the “pioneering and trial” approach in the Lecheng Pilot Zone, using our advanced and dynamic medical platform as the driving force, to jointly create the “Lecheng Pilot Zone Perpetual Pharmaceutical and Medical Device Exhibition and Academic Platform” (樂城先行區永不謝幕藥械展線上學術平台). It will provide efficient, professional and compliant services for physicians across the country to better understand and use pharmaceutical and medical device products in the Lecheng Pilot Zone, establishing a fast lane for medical exchanges and interactions between physicians and patients nationwide. By utilizing the “Medlive Integrated System” (醫脈通醫患一體化系統) to connect physicians and patients within and beyond the Lecheng Pilot Zone, we will meet patients’ demand for the use of special pharmaceutical products in Lecheng and connect real-world data inside and outside the island. We will also provide real-world research services based on the integration of clinical research capabilities of the Hainan Institute of Real World Research (海南省真實世界數據研究院) and Medlive, enabling us to become an important convergence point of domestic and international dual circulation in terms of pharmaceutical, medical device and clinical science innovations. In addition, taking advantage of our platform as a listed company, we will actively seek good quality target enterprises that possess high synergies with our business and further consolidate our leading position within the industry through business integration upon acquisition.
- 探索戰略合作夥伴關係，通過投資及收購整合行業資源。我們將圍繞自有的專業醫師平台，在現有業務的基礎上，繼續擴大與國內外權威機構的戰略合作。今年7月，我們與海南博鳌樂城國際醫療旅遊先行區管理局達成深度戰略合作，雙方的合作將依託樂城先行區「先行先試」的政策優勢，以我們成熟活躍的醫學平台為牽引，共同打造「樂城先行區永不謝幕藥械展線上學術平台」，為全國醫師深入了解和使用樂城先行區的藥械產品提供高效專業且合規的服務，建立全國醫患同樂城先行區醫療交流互動的快車道，利用「醫脈通醫患一體化系統」連通樂城先行區島內島外醫師和患者，滿足患者到樂城使用特許藥械的需求以及聯通島內島外真實世界數據，依託海南省真實世界數據研究院和醫脈通臨床研究一體化能力提供真實世界研究服務，成為創新藥械和臨床科學在國內國際雙循環的重要交匯點。此外，我們將借助上市公司的平台優勢，積極尋找與本集團業務具有高度協同性的優質標的企業，並在收購後進行業務整合，進一步鞏固本公司在行業內的領先地位。

FINANCIAL REVIEW

Revenue

During the first half of 2023, the Group generated revenue from three solution categories, namely (i) precision marketing and corporate solutions; (ii) medical knowledge solutions; and (iii) intelligent patient management solutions. The Group's revenue increased by approximately 31.5% from approximately RMB132.0 million for the six months ended 30 June 2022 to approximately RMB173.5 million for the same period in 2023, primarily due to the revenue increase from its precision marketing and corporate solutions.

Precision Marketing and Corporate Solutions

Revenue from precision marketing solutions is primarily derived from fees paid by the Group's healthcare customers for the Group's digital detailing, digital marketing consulting and digital content creation services. Revenue from corporate solutions is primarily derived from fees paid by the Group's healthcare customers for its digital market research, electronic data capture ("EDC") and clinical data management system ("CDMS") solutions, RWS support solutions, patient recruitment service, as well as application software development service related to precision marketing and corporate solutions.

Revenue from precision marketing and corporate solutions increased by approximately 33.5% from approximately RMB118.4 million for the six months ended 30 June 2022 to approximately RMB158.1 million for the same period in 2023, mainly due to (i) an increase in the Group's healthcare customer base from 84 for the six months ended 30 June 2022 to 124 for the same period in 2023; and (ii) an increase in the number of healthcare products marketed using the Group's precision marketing and corporate solutions from 181 for the six months ended 30 June 2022 to 253 for the same period in 2023, resulting from user growth and increased user engagement as illustrated by the increase in number of paid clicks from approximately 3.18 million for the six months ended 30 June 2022 to approximately 4.27 million for the six months ended 30 June 2023.

財務回顧 收益

2023年上半年，本集團的收益來自三類解決方案，即(i)精準營銷及企業解決方案；(ii)醫學知識解決方案；及(iii)智能患者管理解決方案。本集團的收益由截至2022年6月30日止六個月約人民幣132.0百萬元增加約31.5%至2023年同期約人民幣173.5百萬元，主要是由於精準營銷及企業解決方案收益增加。

精準營銷及企業解決方案

精準營銷解決方案的收益主要來自本集團醫療客戶就本集團數字推送、數字營銷諮詢及數字內容創建服務支付的費用。企業解決方案的收益主要來自本集團醫療客戶就數字市場研究、電子數據採集(「EDC」)及臨床數據管理系統(「CDMS」)解決方案、RWS支持解決方案、患者招募服務及精準營銷及企業解決方案相關應用軟件開發服務支付的費用。

精準營銷及企業解決方案的收益由截至2022年6月30日止六個月約人民幣118.4百萬元增加約33.5%至2023年同期約人民幣158.1百萬元，主要是由於用戶增長及用戶參與度(如付費點擊次數由截至2022年6月30日止六個月的3.18百萬增至截至2023年6月30日止六個月的4.27百萬所顯示)提升的帶動下，(i)本集團醫療客戶群由截至2022年6月30日止六個月的84個增至2023年同期的124個；及(ii)使用本集團精準營銷及企業解決方案進行營銷的醫療產品數目由截至2022年6月30日止六個月的181項增至2023年同期的253項。

Management Discussion and Analysis 管理層討論與分析

Medical Knowledge Solutions

Revenue from medical knowledge solutions is primarily derived from provision of professional medical information covering continuing medical education and clinical decision support, including licensing software to physicians, other registered users, including other healthcare professionals, and pharmaceutical companies. Revenue from medical knowledge solutions increased by approximately 25.5% from approximately RMB6.4 million for the six months ended 30 June 2022 to approximately RMB8.1 million for the same period in 2023, primarily due to the Group's increased offerings of medical knowledge products as well as the introduction of a variety of membership marketing methods, effectively increasing the unit price of users.

Intelligent Patient Management Solutions

Revenue from intelligent patient management solutions was primarily derived from fees paid by non-profit organizations with medical focus and pharmaceutical companies for provision of patient education services to patients and non-profit organizations, including content development, application software development and other related services. The Group also started to generate revenue from commissions on fees paid by patients for online consultation services and prescription services on its Internet hospital since the first half of 2021. Revenue from intelligent patient management solutions increased by approximately 3.5% from approximately RMB7.1 million for the six months ended 30 June 2022 to approximately RMB7.3 million for the same period in 2023, mainly due to the gradual recovery and improvement of the emphasis on patient education and patient management by non-profit medical organizations and pharmaceutical companies after the pandemic.

醫學知識解決方案

醫學知識解決方案的收益主要來自提供涵蓋持續醫學教育及臨床決策支持的專業醫學信息，包括向醫師、其他註冊用戶(包括其他醫療專業人員)及製藥公司授權軟件使用。醫學知識解決方案的收益由截至2022年6月30日止六個月的約人民幣6.4百萬元增加約25.5%至2023年同期約人民幣8.1百萬元，主要是由於本集團提供了更多醫學知識產品，同時新增了多種會員營銷方式，令用戶單價得到有效提升。

智能患者管理解決方案

智能患者管理解決方案的收益主要來自非牟利醫學組織及製藥公司就向患者及非牟利組織提供的患者教育服務(包括內容開發、應用軟件開發及其他相關服務)支付的費用。自2021年上半年起，本集團亦開始自患者就使用互聯網醫院的在線諮詢服務及處方服務而支付的費用中賺取佣金收益。智能患者管理解決方案的收益由截至2022年6月30日止六個月約人民幣7.1百萬元增加約3.5%至2023年同期約人民幣7.3百萬元，主要是由於疫情後非盈利醫學組織及製藥公司對患者教育及患者管理的重視程度在逐步恢復及提升。

Cost of sales

The Group's cost of sales consists of (i) employee benefit expenses relating to salaries and benefits for employees involved in operating the Group's platform and developing content; (ii) content development cost primarily relating to fees paid to content contributors and service fees paid to content production service providers; (iii) technology service fees relating to cloud content delivery network and telecommunication services as well as licensing fees; and (iv) other expenses primarily relating to consulting fees, equipment rental expenses, travel and transportation expenses. The Group's cost of sales increased by approximately 67.7% from approximately RMB40.7 million for the six months ended 30 June 2022 to approximately RMB68.3 million for the same period in 2023. The increase was primarily due to the fact that in 2023, the cost ratio of newly acquired subsidiaries and clinical research projects is higher than that of traditional precision marketing projects, resulting in a higher rate of growth in cost as compared with the growth rate of revenue.

Gross profit and gross profit margin

As a result of the foregoing, the Group's gross profit increased by approximately 15.3% to approximately RMB105.2 million for the six months ended 30 June 2023 from approximately RMB91.2 million for the same period in 2022. The Group's gross profit margin was approximately 60.6% for the six months ended 30 June 2023, which decreased from 69.1% for the same period in 2022.

Other Income

Other income and gains primarily consist of (i) bank interest income; (ii) investment income from financial assets at fair value through profit or loss; and (iii) government subsidy. The Group recorded other income and gains of approximately RMB82.8 million for the six months ended 30 June 2023, compared to approximately RMB26.0 million for the same period in 2022. The increase was primarily attributable to (i) a substantial increase in interest income derived from bank deposits as a result of repeated increase in market interest rates in 2022; and (ii) recognition of government subsidy.

銷售成本

本集團的銷售成本包括(i)有關經營本集團平台及開發內容的僱員薪金及福利的僱員福利開支；(ii)主要有關向內容貢獻者支付的内容開發費用及向内容製作服務供應商支付的服務費；(iii)有關雲内容交付網絡及電信服務的技術服務費以及許可費；及(iv)主要有關顧問費、設備租賃開支、差旅及交通開支的其他開支。本集團的銷售成本由截至2022年6月30日止六個月約人民幣40.7百萬元增加約67.7%至2023年同期約人民幣68.3百萬元，主要是由於2023年新增的併購附屬公司及臨床研究項目成本率均高於傳統的精準營銷項目，造成成本的增長大於收益增長的幅度。

毛利及毛利率

基於上述理由，本集團的毛利由截至2022年6月30日止六個月約人民幣91.2百萬元增加約15.3%至2023年同期約人民幣105.2百萬元。截至2023年6月30日止六個月，本集團的毛利率約為60.6%，較2022年同期的69.1%有所下降。

其他收入

其他收入及收益主要包括(i)銀行利息收入；(ii)按公允價值計量且其變動計入當期損益的金融資產的投資收入；及(iii)政府補貼。截至2023年6月30日止六個月，本集團錄得其他收入及收益約人民幣82.8百萬元，而2022年同期則約為人民幣26.0百萬元，增加主要是由於(i)銀行存款所得利息收入大幅增加，是因2022年內市場利率多次調升所致；及(ii)確認政府補貼。

Management Discussion and Analysis

管理層討論與分析

Selling and Distribution Expenses

The Group's selling and distribution expenses primarily consist of (i) expenses for promotion activities to drive user growth and engagement; (ii) employee benefit expenses relating to salaries and benefits for employees in selling and distribution functions; and (iii) other expenses primarily relating to business development expenses. The Group's selling and distribution expenses decreased by approximately 0.7% from approximately RMB16.1 million for the six months ended 30 June 2022 to approximately RMB16.0 million for the same period in 2023, primarily due to the Group's vigorous implementation of various cost reduction and efficiency improvement measures to effectively control the growth of selling and distribution expenses.

Administrative Expenses

The Group's administrative expenses primarily consist of (i) research and development costs primarily relating to salaries and benefits for employees in research and development functions; (ii) employee benefit expenses relating to salaries and benefits for employees in management as well as general and administrative functions; (iii) depreciation of assets, which includes depreciation of right-of-use assets relating to the Group's leases and depreciation of property, plant and equipment; (iv) taxes and surcharges; (v) maintenance expenses primarily relating to technology and telecommunication service fees, as well as service fees for outsourced administrative services; and (vi) other expenses primarily relating to rent, travel and transportation expenses and general office expenses. The Group's administrative expenses increased by approximately 12.6% from approximately RMB51.0 million for the six months ended 30 June 2022 to approximately RMB57.4 million for the same period in 2023, primarily due to recognition of (i) increased expenses in maintaining and upgrading the *Medlive* platform, in particular, the investment in vertical large models in the medical field has increased; and (ii) increase in research and development fees, while other administrative expenses have been effectively controlled.

銷售及分銷開支

本集團的銷售及分銷開支主要包括(i)促進用戶增長及參與度的宣傳活動開支;(ii)有關銷售及分銷僱員薪金及福利的僱員福利開支;及(iii)主要與業務發展開支有關的其他開支。本集團的銷售及分銷開支由截至2022年6月30日止六個月約人民幣16.1百萬元減少約0.7%至2023年同期約人民幣16.0百萬元,主要是由於本集團有力執行各項降本增效措施,有效控制銷售及分銷開支增長。

行政開支

本集團的行政開支主要包括(i)主要有關研發僱員薪金及福利的研發開支;(ii)有關一般及行政管理僱員薪金及福利的僱員福利開支;(iii)資產折舊,包括有關本集團租賃的使用權資產的折舊以及物業、廠房及設備的折舊;(iv)稅項及附加費;(v)主要與技術、電信服務的服務費以及外包行政服務的服務費有關的維護開支;及(vi)主要有關租金、差旅及交通開支及一般辦公室開支的其他開支。本集團的行政開支由截至2022年6月30日止六個月約人民幣51.0百萬元增加約12.6%至2023年同期約人民幣57.4百萬元,主要由於確認(i)醫脈通平台維護及升級費用增加,特別是醫療領域垂直大模型的投入增加;及(ii)研發費用增加,而其他的行政開支則得到有效控制。

Finance Costs

The Group's finance costs consist of finance costs allocated from lease payments. Finance costs are charged to profit or loss over the lease periods so as to produce a constant periodic rate of interest on the remaining balance of the liabilities for each period. Lease liabilities decrease over the periods of the leases, resulting in higher finance costs at the beginning of lease periods. The Group's finance costs decreased by approximately 30.9% from approximately RMB0.3 million for the six months ended 30 June 2022 to approximately RMB0.2 million for the same period in 2023.

Profit Before Tax

As a result of the foregoing, the Group's profit before tax increased by approximately 202.9% from approximately RMB33.9 million for the six months ended 30 June 2022 to approximately RMB102.7 million for the same period in 2023.

Income Tax Expenses

The Group's income tax expense decreased by approximately 83.9% from approximately RMB6.2 million for the six months ended 30 June 2022 to approximately RMB1.0 million for the same period in 2023, primarily because during the first six months of 2022, the share options granted under the Pre-IPO Share Option Scheme have not commenced vesting and exercise and the related share-based compensation is not eligible for income tax deduction whereas after the commencement of vesting and exercise of share options in July 2022, share-based compensation is eligible for income tax deduction, resulting in a reduction in income tax expenses.

Profit for the Period and Profit Attributable to Owners of the Parent

As a result of the foregoing, the Group's profit for the period increased by approximately 267.5% from approximately RMB27.7 million for the six months ended 30 June 2022 to approximately RMB101.7 million for the same period in 2023 and the Group's profit attributable to owners of the parent increased by approximately 266.0% from approximately RMB27.0 million to approximately RMB98.7 million.

The Group's net profit margin (calculated on the basis of the profit for the period) increased by 37.6 percentage points from approximately 21.0% for the six months ended 30 June 2022 to approximately 58.6% for the same period in 2023.

融資成本

本集團的融資成本包括自租賃付款分配的融資成本。融資成本於租賃期內自損益扣除，以得出各期間負債結餘的定期固定利率。租賃負債於租賃期內減少，導致融資成本於租賃期開始時上升。本集團的融資成本由截至2022年6月30日止六個月約人民幣0.3百萬元減少約30.9%至2023年同期約人民幣0.2百萬元。

除稅前溢利

基於上述理由，本集團的除稅前溢利由截至2022年6月30日止六個月約人民幣33.9百萬元增加約202.9%至2023年同期約人民幣102.7百萬元。

所得稅開支

本集團的所得稅開支由截至2022年6月30日止六個月約人民幣6.2百萬元減少約83.9%至2023年同期約人民幣1.0百萬元，主要由於2022年前六個月根據首次公開發售前購股權計劃授出的購股權還未開始歸屬行權，股份支付薪酬不可以抵扣所得稅，而2022年7月開始歸屬行權後，股份支付薪酬可以抵扣所得稅，使得所得稅開支減少。

期間溢利及母公司擁有人應佔溢利

基於上述理由，本集團的期間溢利由截至2022年6月30日止六個月約人民幣27.7百萬元增加約267.5%至2023年同期約人民幣101.7百萬元，而本集團的母公司擁有人應佔溢利由約人民幣27.0百萬元增加約266.0%至約人民幣98.7百萬元。

本集團的淨利潤率(以期間溢利計算)由截至2022年6月30日止六個月的約21.0%增加37.6個百分點至2023年同期的約58.6%。

Management Discussion and Analysis 管理層討論與分析

Non-HKFRS Measures — Adjusted Net Profit

To supplement the Group's consolidated financial statements which are presented in accordance with Hong Kong Financial Reporting Standards ("HKFRS"), the Company also used unaudited non-HKFRS adjusted net profit as an additional financial measure in order to evaluate its financial performance by eliminating the impact of items that it does not consider indicative of the performance of its business. The term "adjusted net profit" is not defined under HKFRS. Other companies in the industry which the Group operates in may calculate such non-HKFRS item differently from the Group. The use of adjusted net profit has material limitations as an analytical tool, as adjusted net profit does not include all items that impact the Group's net profit for the Reporting Period and should not be considered in isolation or as a substitute for analysis of the Group's results as reported under HKFRS.

The following table sets out the calculation of adjusted net profit for the periods indicated:

		Six months ended 30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Profit for the period	期間溢利	101,659	27,665
Add:	加：		
Share-based compensation	股份支付薪酬	6,376	10,629
Foreign exchange difference	匯兌差異	11,764	15,660
Adjusted net profit	經調整淨溢利	119,799	53,954

The adjusted net profit for the six months ended 30 June 2023, adjusted by excluding share-based compensation to key employees and foreign exchange difference, was approximately RMB119.8 million, which was approximately 122.0% higher than the adjusted net profit of approximately RMB54.0 million for the first half of 2022.

The adjusted net profit margin for the six months ended 30 June 2023 was approximately 69.0%, up 28.1 percentage points from approximately 40.9% for the same period in 2022.

非香港財務報告準則計量 — 經調整淨溢利

為補充本集團根據香港財務報告準則(「香港財務報告準則」)呈列的綜合財務報表，本公司亦使用未經審核非香港財務報告準則經調整淨溢利作為額外財務計量，透過撇除我們認為並非業務表現指標項目的影響，以評估其財務表現。香港財務報告準則並無界定「經調整淨溢利」一詞。本集團經營所處行業的其他公司計算該非香港財務報告準則項目的方式可能與本集團不同。經調整淨溢利用作分析工具有重大限制，原因是經調整淨溢利並未包括影響本集團報告期間淨溢利的所有項目，因此不應獨立考慮或作為根據香港財務報告準則報告的本集團業績分析的替代。

下表載列所示期間經調整淨溢利的計算：

截至2023年6月30日止六個月，經調整淨溢利(經撇除重要僱員的股份支付薪酬及匯兌差異後調整)約為人民幣119.8百萬元，較2022年上半年約人民幣54.0百萬元增加約122.0%。

截至2023年6月30日止六個月的經調整淨利潤率約69.0%，較2022年同期的約40.9%增加28.1個百分點。

Liquidity and Capital Resources

For the six months ended 30 June 2023, the Group financed its operations primarily through cash generated from the Group's operating activities and the net proceeds received from the global offering of shares of the Company (the “**Global Offering**”). The Group intends to finance its expansion and business operations using a combination of cash generated from operating activities and the net proceeds received from the Global Offering.

The Group has adopted a prudent financial management approach towards its treasury policy. The Board closely monitors the Group's liquidity position to ensure that the liquidity structure of the Group's assets, liabilities, and other commitments can meet its funding requirements from time to time.

The net proceeds received by the Company from the Global Offering which are not yet put into use have been placed in fixed deposits with licensed financial institutions. Please refer to the section headed “Use of Proceeds from the Global Offering” for details regarding the use of idle proceeds from the Global Offering.

Cash and cash equivalents

The Group operates its business in the PRC and its transactions and revenue were primarily denominated in Renminbi. As such, the Group did not have material exposure to fluctuations in foreign currency exchange rates for cash generated from its operating activities. However, the net proceeds received by the Company from the Global Offering are denominated in Hong Kong dollars and the Company is exposed to fluctuation of exchange rate between Renminbi and Hong Kong dollars. As at 30 June 2023, the Group had cash and cash equivalents of approximately RMB4,373.3 million, which primarily consisted of cash at bank, as compared to approximately RMB4,187.3 million as of 31 December 2022. As at 30 June 2023, around 32.4% of the Group's cash and cash equivalents are denominated in Hong Kong dollars, around 9.8% are denominated in RMB and around 57.8% are denominated in US dollars.

The Group currently does not have any hedging policy for foreign currencies in place. However, the Board will remain alert to any relevant risks and, if necessary, consider to hedge any material potential foreign exchange risk.

流動資金及資本資源

截至2023年6月30日止六個月，本集團主要通過本集團經營活動所得現金和本公司全球發售股份（「**全球發售**」）所得款項淨額籌集營運資金。本集團擬利用經營活動所得現金和全球發售所得款項淨額為擴張及業務運營提供資金。

本集團對其財務政策採取審慎的財務管理辦法。董事會密切監察本集團的流動資金狀況，確保本集團的資產、負債及其他承諾的流動資金結構能不時滿足其資金需求。

本公司從全球發售獲得的所得款項淨額尚未投入使用部分已存入持牌金融機構作定期存款。有關閒置的全球發售所得款項的使用情況，請參閱下文「全球發售所得款項用途」一節。

現金及現金等價物

本集團在中國經營業務，其交易及收益主要以人民幣計值。因此，本集團在經營活動所得現金方面並無面對外幣匯率波動的重大風險。然而，本公司從全球發售獲得的所得款項淨額以港元計值，本公司面對人民幣與港元之間匯率波動的風險。於2023年6月30日，本集團有現金及現金等價物約人民幣4,373.3百萬元（主要包括銀行現金），而截至2022年12月31日約為人民幣4,187.3百萬元。於2023年6月30日，本集團約32.4%的現金及現金等價物以港元計值，約9.8%以人民幣計值，約57.8%以美元計值。

本集團目前並無任何外匯對沖政策。然而，董事會仍會警惕任何相關風險，在必要時會考慮對沖任何重大潛在匯率風險。

Management Discussion and Analysis 管理層討論與分析

Borrowings

During the six months ended 30 June 2023, the Group did not have any short-term or long-term bank borrowings and had no outstanding bank and other borrowings and other indebtedness apart from lease liabilities for the relevant lease terms amounting to approximately RMB0.2 million in aggregate.

Gearing ratio

The gearing ratio, which is calculated by dividing borrowings by total equity, was zero since there was no debt as of 30 June 2023.

Charge on assets

As of 30 June 2023, the Group did not pledge any of its assets.

Capital expenditures

For the six months ended 30 June 2023, the Group's capital expenditure amounted to approximately RMB46.7 million, which mainly comprised capital expenditures recorded for the acquisition of 60% interest in Beijing Medcon Information Consulting Co., Ltd.* (北京美迪康信息諮詢有限公司) and 50% interest in SCMedcon and expenditures on IT equipment, as compared to approximately RMB45.6 million for the same period in 2022. The Group funded its capital expenditure by using the cash flow generated from its operations and the net proceeds received from the Global Offering.

Contingent liabilities and guarantees

As of 30 June 2023, the Group did not have any significant unrecorded contingent liabilities, guarantees or any material litigation against the Group.

Material acquisitions or disposals and future plans for major investment

On 12 June 2023, Kingyee (Beijing) Co., Ltd. (金葉天成(北京)科技有限公司) (“**Kingyee Beijing**”), an indirect wholly-owned subsidiary of the Company, entered into an equity transfer agreement pursuant to which Kingyee Beijing acquired 50% equity interest of SCMedcon for a cash consideration of RMB65,000,000.

借款

截至2023年6月30日止六個月，本集團並無任何短期或長期銀行借款，除總計約人民幣0.2百萬元的相關租賃條款的租賃負債外，亦無未償還銀行及其他借款及其他債務。

資產負債比率

由於截至2023年6月30日並無債務，資產負債比率(按借款除以權益總額計算)為零。

資產抵押

於2023年6月30日，本集團並無抵押任何資產。

資本開支

截至2023年6月30日止六個月，本集團的資本開支約為人民幣46.7百萬元(主要包括錄得收購北京美迪康信息諮詢有限公司60%權益及石成醫學50%權益的資本開支及IT設備開支)，而2022年同期約為人民幣45.6百萬元。本集團以營運所得現金流量和全球發售所得款項淨額為資本開支提供資金。

或然負債及擔保

於2023年6月30日，本集團並無任何重大的未入賬或然負債、擔保或針對本集團的任何重大訴訟。

重大收購或出售及主要投資未來計劃

於2023年6月12日，本公司間接全資附屬公司金葉天成(北京)科技有限公司(「**金葉天成北京**」)訂立股權轉讓協議，據此，金葉天成北京收購石成醫學50%的股權，現金代價為人民幣65,000,000元。

SCMedcon is principally engaged in the business of organising medical exhibition conferences and exchange meetings for pharmaceutical and medical devices companies and institutions serving the medical industry, and provision of related medical training services and medical content services. Utilising the expertise of its employees, SCMedcon is also engaged in the provision of a comprehensive range of management consulting and medical technology services to pharmaceutical and medical devices companies such as the production of medical knowledge materials and medical data management and analysis.

The sellers of the 50% interests in SCMedcon have undertaken to ensure that the accumulated audited net profit of SCMedcon for the four years ending 31 December 2023, 2024, 2025 and 2026 in total shall be no less than RMB58,080,000 (the “**Guaranteed Profit**”). The cash consideration of RMB65,000,000 is payable in five instalments. The first instalment of RMB35,750,000 has been paid. The remaining amount is payable over the next four years after the audited financial results of the Group and SCMedcon for the relevant year have been issued. The consideration may be adjusted downwards if the Guaranteed Profit is not met.

The sellers have also granted an option to Kingyee Beijing so that if less than 55% of the Guaranteed Profit is met, Kingyee Beijing has the right, but not an obligation, to require the sellers to repurchase interests in SCMedcon held by Kingyee Beijing. Further details of the acquisition are set out in the Company’s announcement dated 12 June 2023. The acquisition completed in June 2023.

The Group will continue to selectively pursue suitable strategic investments and acquisitions that can generate convincing synergies with the Group’s existing solutions offerings, expand its customer base and/or enhance its technological capabilities. The Group will utilize proceeds from the Global Offering for the purpose of any such acquisition.

石成醫學主要從事為製藥及醫療器械公司及服務於醫療行業的機構組織醫療展會及交流會，並提供相關醫學培訓服務及醫學內容服務。利用其僱員的專業知識，石成醫學亦從事為製藥及醫療器械公司提供全面的管理諮詢和醫學技術服務，例如製作醫學知識材料及醫學數據管理及分析。

石成醫學50%股權的賣方承諾保證石成醫學截至2023年、2024年、2025年及2026年12月31日止四個年度的累計經審核淨利潤合共不低於人民幣58,080,000元（「保證利潤」）。現金代價人民幣65,000,000元分五期支付。第一期人民幣35,750,000元已支付。餘款須於本集團及石成醫學相關年度的經審核財務業績公佈後的未來四年內支付。倘未能達到保證利潤，代價可能會向下調整。

賣方亦已向金葉天成北京授予選擇權，若低於保證利潤的55%獲達成，金葉天成北京有權但無責任要求賣方購回金葉天成北京所持石成醫學的權益。收購事項的詳情載於本公司日期為2023年6月12日之公告。收購於2023年6月完成交割。

本集團將繼續精心挑選可與本集團現有解決方案產品產生令人信服的協同效應、擴大客戶群及／或提升技術能力的適當戰略投資及收購。本集團會以全球發售所得款項用於任何該等收購。

Management Discussion and Analysis 管理層討論與分析

Employees and Staff Costs

As of 30 June 2023, the Group had a total of 668 full time employees, all of whom, except for one employee based in Hong Kong, were located in mainland China. In particular, 153 employees are responsible for the Group's content management, 216 employees for platform operation and customer service, 158 employees for research and development, 71 employees for general and administration and 70 employees for sales and marketing. The total staff cost incurred by the Group for the six months ended 30 June 2023 was approximately RMB67.1 million compared to approximately RMB67.8 million for the same period in 2022. The decrease was primarily due to the Group fully implementing various measures to reduce costs and increase efficiency, striving to improve human efficiency and reduce costs.

The Group provides orientation and training to new recruits as well as ongoing in-house training for junior employees, which the Group believes can enhance the skills and productivity of its employees. The Group compensates employees with base salaries and performance-based bonuses. The Company has also adopted a pre-IPO share option scheme, a post-IPO share option scheme and a share award scheme to incentivize employees and senior management and to align their interests with that of the Company.

Further details of the principal terms of the abovementioned share incentive schemes are set out in the 2022 annual report of the Company.

僱員及員工成本

於2023年6月30日，本集團共有668名全職僱員，除了一位在香港任職外，全部均位於中國內地。具體而言，153名僱員負責本集團內容管理、216名僱員負責平台營運及客戶服務、158名僱員負責研發、71名僱員負責一般及行政及70名僱員負責銷售及營銷。截至2023年6月30日止六個月，本集團產生的員工成本總額約為人民幣67.1百萬元，而2022年同期約為人民幣67.8百萬元。減少主要是由於本集團全面實行各項降本增效措施，努力提升人效，降低成本。

本集團為新入職員工提供入職培訓，並為初級僱員提供持續內部培訓，本集團認為該等培訓可提高僱員的技能及生產力。本集團以基本薪金及績效花紅向僱員支付薪酬。本公司亦採用首次公開發售前購股權計劃、首次公開發售後購股權計劃及股份獎勵計劃，以激勵僱員及高級管理層，使其利益與本公司的利益一致。

上述股份激勵計劃主要條款的更多詳情載於本公司2022年年報。

Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 未經審核中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 截至6月30日止六個月

		Notes 附註	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
REVENUE	收益	4	173,506	131,953
Cost of sales	銷售成本		(68,283)	(40,710)
Gross profit	毛利		105,223	91,243
Other income and gains	其他收入及收益	4	82,848	26,033
Selling and distribution expenses	銷售及分銷開支		(16,000)	(16,115)
Administrative expenses	行政開支		(57,420)	(50,988)
Other expenses	其他開支		(11,796)	(16,000)
Finance costs	融資成本		(195)	(282)
Share of profit of an associate	分佔聯營公司溢利		3	—
PROFIT BEFORE TAX	除稅前溢利	5	102,663	33,891
Income tax expense	所得稅開支	6	(1,004)	(6,226)
PROFIT FOR THE PERIOD	期間溢利		101,659	27,665
Attributable to:	以下人士應佔：			
Owners of the parent	母公司擁有人		98,718	26,973
Non-controlling interests	非控股權益		2,941	692
			101,659	27,665
OTHER COMPREHENSIVE INCOME	其他全面收益			
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:	於後續期間不會重新分類至損益的其他全面收益：			
Exchange differences on translation of the Company's financial statements into presentation currency	換算為本公司財務報表呈列貨幣之匯兌差異		146,835	191,838
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	期內其他全面收益		146,835	191,838
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額		248,494	219,503

Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 未經審核中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 截至6月30日止六個月

			2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 <i>RMB'000</i> 人民幣千元 (Unaudited) (未經審核)
		<i>Notes</i> 附註		
Attributable to:	以下人士應佔：			
Owners of the parent	母公司擁有人		245,553	218,811
Non-controlling interests	非控股權益		2,941	692
			248,494	219,503
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通權益持有人 應佔每股盈利			
Basic	基本	8	RMB13.75 cents 人民幣13.75分	RMB3.78 cents 人民幣3.78分
Diluted	攤薄	8	RMB13.39 cents 人民幣13.39分	RMB3.65 cents 人民幣3.65分

Unaudited Interim Condensed Consolidated Statement of Financial Position

未經審核中期簡明綜合財務狀況表

		Notes	30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
		附註		
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備		2,898	3,268
Right-of-use assets	使用權資產		8,712	11,304
Goodwill	商譽	12	170,682	111,518
Other intangible assets	其他無形資產		29,357	24,336
Investment in an associate	於聯營公司的投資		358	355
Time deposits	定期存款		93,966	92,438
Deferred tax assets	遞延稅項資產		9,461	8,283
Total non-current assets	非流動資產總值		315,434	251,502
CURRENT ASSETS	流動資產			
Inventories	存貨		209	199
Trade receivables	貿易應收款項	9	91,575	95,079
Contract assets	合約資產		43,148	29,132
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產		19,458	10,413
Financial assets at fair value through profit or loss	按公允價值計量且其變動計入損益的金融資產		39,650	29,640
Cash and cash equivalents	現金及現金等價物		4,373,272	4,187,264
Total current assets	流動資產總值		4,567,312	4,351,727
CURRENT LIABILITIES	流動負債			
Trade payables	貿易應付款項	10	3,679	2,709
Other payables and accruals	其他應付款項及應計費用		97,333	85,913
Contingent consideration payables	應付或然代價		42,768	13,956
Lease liabilities	租賃負債		4,317	5,136
Tax payable	應付稅項		20,784	25,032
Due to a related party	應付關聯方款項		280	—
Dividend payable	應付股息		46,678	—
Total current liabilities	流動負債總額		215,839	132,746
NET CURRENT ASSETS	流動資產淨值		4,351,473	4,218,981
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債		4,666,907	4,470,483

Unaudited Interim Condensed Consolidated Statement of Financial Position

未經審核中期簡明綜合財務狀況表

		30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
	Note 附註		
NON-CURRENT LIABILITIES	非流動負債		
Lease liabilities	租賃負債	4,216	6,126
Contingent consideration payables	應付或然代價	18,221	27,803
Deferred tax liabilities	遞延稅項負債	3,129	4,640
Total non-current liabilities	非流動負債總額	25,566	38,569
Net assets	資產淨值	4,641,341	4,431,914
EQUITY	權益		
Equity attributable to owners of the parent	母公司擁有人應佔權益		
Share capital	股本	45	45
Reserves	儲備	4,606,229	4,400,978
		4,606,274	4,401,023
Non-controlling interests	非控股權益	35,067	30,891
Total equity	權益總額	4,641,341	4,431,914

Unaudited Interim Condensed Consolidated Statement of Changes in Equity

未經審核中期簡明綜合權益變動表

For the six months ended 30 June 2023

截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔								
Notes 附註		Share capital 股本 RMB'000 人民幣千元	Share premium* 股份溢價賬* RMB'000 人民幣千元	Share option reserve* 購股權儲備* RMB'000 人民幣千元	Statutory surplus reserve* 法定盈餘儲備* RMB'000 人民幣千元	Exchange fluctuation reserve* 匯兌波動儲備* RMB'000 人民幣千元	Retained profits* 留存溢利* RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元	Non-controlling interests 非控股權益 RMB'000 人民幣千元	Total equity 權益總計 RMB'000 人民幣千元
	At 1 January 2023 (audited)	45	3,898,396	31,502	19,174	276,623	175,283	4,401,023	30,891	4,431,914
	Profit for the period (unaudited)	-	-	-	-	-	98,718	98,718	2,941	101,659
	Other comprehensive income for the period (unaudited)	-	-	-	-	-	-	-	-	-
	Exchange differences	-	-	-	-	146,835	-	146,835	-	146,835
	Total comprehensive income for the period (unaudited)	-	-	-	-	146,835	98,718	245,553	2,941	248,494
	Acquisition of a subsidiary (unaudited)	-	-	-	-	-	-	-	5,836	5,836
	Dividends paid to non-controlling shareholders (unaudited)	-	-	-	-	-	-	-	(4,601)	(4,601)
	Equity-settled share award arrangements (unaudited)	-	-	6,376	-	-	-	6,376	-	6,376
	Final 2022 dividend declared (unaudited)	-	-	-	-	-	(46,678)	(46,678)	-	(46,678)
	At 30 June 2023 (unaudited)	45	3,898,396	37,878	19,174	423,458	227,323	4,606,274	35,067	4,641,341

* These reserve accounts comprise the consolidated reserves of RMB4,606,229 in the interim condensed consolidated statement of financial position as at 30 June 2023.

* 該等儲備賬構成於2023年6月30日的中期簡明綜合財務狀況表中的綜合儲備為人民幣4,606,229元。

For the six months ended 30 June 2022

截至2022年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔								
Notes 附註		Share capital 股本 RMB'000 人民幣千元	Share premium 股份溢價賬 RMB'000 人民幣千元	Share option reserve 購股權儲備 RMB'000 人民幣千元	Statutory surplus reserve 法定盈餘儲備 RMB'000 人民幣千元	Exchange fluctuation reserve 匯兌波動儲備 RMB'000 人民幣千元	Retained profits 留存溢利 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元	Non-controlling interests 非控股權益 RMB'000 人民幣千元	Total equity 權益總計 RMB'000 人民幣千元
	At 1 January 2022 (audited)	44	3,898,396	14,257	13,640	(53,264)	75,629	3,948,702	23,491	3,972,193
	Profit for the period (unaudited)	-	-	-	-	-	26,973	26,973	692	27,665
	Other comprehensive income for the period (unaudited)	-	-	-	-	-	-	-	-	-
	Exchange differences	-	-	-	-	191,838	-	191,838	-	191,838
	Total comprehensive income for the period (unaudited)	-	-	-	-	191,838	26,973	218,811	692	219,503
	Acquisition of a subsidiary (unaudited)	-	-	-	-	-	-	-	2,932	2,932
	Dividends paid to non-controlling shareholders (unaudited)	-	-	-	-	-	-	-	(4,704)	(4,704)
	Equity-settled share award arrangements (unaudited)	-	-	10,629	-	-	-	10,629	-	10,629
	Final 2021 dividend declared (unaudited)	-	-	-	-	-	(12,133)	(12,133)	-	(12,133)
	At 30 June 2022 (unaudited)	44	3,898,396	24,886	13,640	138,574	90,469	4,166,009	22,411	4,188,420

Unaudited Interim Condensed Consolidated Statement of Cash Flows 未經審核中期簡明綜合現金流量表

For the six months ended 30 June 截至6月30日止六個月

		2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動所得現金流量		
Profit before tax	除稅前溢利	102,663	33,891
Adjustments for:	就下列各項作出調整：		
Finance costs	融資成本	195	282
Share of profit of an associate	分佔聯營公司溢利	(3)	—
Interest income	利息收入	(71,014)	(2,445)
Investment income from financial assets at fair value through profit or loss	按公允價值計量且其變動計入損益的金融資產投資收入	(367)	(384)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	802	663
Depreciation of right-of-use assets	使用權資產折舊	2,592	2,899
Amortisation of other intangible assets	其他無形資產攤銷	929	546
Impairment of trade receivables, net	貿易應收款項減值淨額	—	155
Loss on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損	—	8
Fair value adjustment of contingent consideration	或然代價公允價值調整	—	330
Equity-settled share award expense	以權益結算的股份獎勵開支	6,376	10,629
		42,173	46,574
Increase in inventories	存貨增加	(10)	(117)
Decrease in trade receivables	貿易應收款項減少	6,996	8,981
Increase in contract assets	合約資產增加	(12,252)	(12,495)
(Increase)/decrease in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產(增加)/減少	(5,939)	676
Increase/(decrease) in trade payables	貿易應付款項增加/(減少)	152	(3,548)
Increase/(decrease) in other payables and accruals	其他應付款項及應計費用增加/(減少)	8,676	(6,134)
Cash generated from operations	經營所得現金	39,796	33,937
Income tax paid	已付所得稅	(9,476)	(5,371)
Net cash flows from operating activities	經營活動所得現金流量淨額	30,320	28,566

Unaudited Interim Condensed Consolidated Statement of Cash Flows 未經審核中期簡明綜合現金流量表

For the six months ended 30 June 截至6月30日止六個月

			2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金流量			
Interest received	已收利息		69,485	2,445
Increase in time deposit	定期存款增加		(3,975,523)	—
Investment income from financial assets at fair value through profit or loss	按公允價值計量且其變動計入損益的金融資產投資收入		367	384
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目		(390)	(1,211)
Additions to other intangible assets	添置其他無形資產		(5,950)	(2,350)
Purchase of financial assets at fair value through profit or loss	購買按公允價值計量且其變動計入損益的金融資產		(5,000)	—
Proceeds from disposal of financial assets at fair value through profit or loss	出售按公允價值計量且其變動計入損益的金融資產所得款項		1,400	—
Payment of contingent considerations for acquisition of a subsidiary	支付收購附屬公司的或然代價		(10,020)	(20,050)
Acquisition of a subsidiary	收購附屬公司	12	(30,314)	(22,553)
Net cash flows used in investing activities	投資活動所用現金流量淨額		(3,955,945)	(43,335)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金流量			
Dividend paid to non-controlling shareholders	已付非控股股東股息		(4,601)	(4,704)
Principal portion of lease payments	租賃付款本金部分		(2,729)	(2,768)
Interest paid for lease liabilities	租賃負債的已付利息		(195)	(282)
Dividend paid to the then shareholders of a subsidiary	已付附屬公司當時股東股息		(3,200)	—
Net cash flows used in financing activities	融資活動所用現金流量淨額		(10,725)	(7,754)
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物淨減少		(3,936,350)	(22,523)
Cash and cash equivalents at beginning of period	期初現金及現金等價物		4,187,264	3,879,104
Effect of foreign exchange rate changes, net	匯率變動的影響淨額		146,835	191,838

Unaudited Interim Condensed Consolidated Statement of Cash Flows 未經審核中期簡明綜合現金流量表

For the six months ended 30 June 截至6月30日止六個月

		2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末現金及及現金 等價物	397,749	4,048,419
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等價物 結餘分析		
Cash and bank balances	現金及銀行結餘	39,888	4,048,419
Time deposits	定期存款	4,427,350	—
Less: Non-current time deposits	減：非流動定期存款	93,966	—
Cash and cash equivalents as stated in the statement of financial position	財務狀況表所列現金及 現金等價物	4,373,272	4,048,419
Time deposits with original maturity of over three months when acquired	獲得時原到期日超過 三個月的定期存款	(3,975,523)	—
Cash and cash equivalents as stated in the statement of cash flows	現金流量表所列現金及 現金等價物	397,749	4,048,419

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2023 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2022.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2022, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

HKFRS 17	<i>Insurance Contracts</i>
Amendments to HKFRS 17	<i>Insurance Contracts</i>
Amendment to HKFRS 17	<i>Initial Application of HKFRS 17 and HKFRS 9 – Comparative Information</i>
Amendments to HKAS 1 and HKFRS Practice Statement 2	<i>Disclosure of Accounting Policies</i>
Amendments to HKAS 8	<i>Definition of Accounting Estimates</i>
Amendments to HKAS 12	<i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>
Amendments to HKAS 12	<i>International Tax Reform – Pillar Two Model Rules</i>

1. 編製基準

截至2023年6月30日止六個月的中期簡明綜合財務資料乃根據香港會計準則第34號*中期財務報告*編製。中期簡明綜合財務資料並無包括年度財務報表規定的所有資料及披露，並應與本集團截至2022年12月31日止年度的年度綜合財務報表一併閱讀。

2. 會計政策及披露事項變動

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2022年12月31日止年度的年度綜合財務報表所應用者一致，惟就本期財務資料首次採納下列新訂及經修訂香港財務報告準則（「香港財務報告準則」）除外。

香港財務報告準則第17號	<i>保險合約</i>
香港財務報告準則第17號(修訂本)	<i>保險合約</i>
香港財務報告準則第17號(修訂本)	<i>首次應用香港財務報告準則第17號及香港財務報告準則第9號 – 比較資料</i>
香港會計準則第1號及會計政策之披露	<i>香港財務報告準則實務報告第2號(修訂本)</i>
香港會計準則第8號(修訂本)	<i>會計估計之定義</i>
香港會計準則第12號(修訂本)	<i>與單一交易產生之資產及負債有關的遞延稅項</i>
香港會計準則第12號(修訂本)	<i>國際稅收改革 – 支柱二立法模板</i>

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

The nature and impact of the new and revised HKFRSs that are applicable to the Group are described below:

- (a) Amendments to HKAS 1 require entities to disclose their material accounting policy information rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. Amendments to HKFRS Practice Statement 2 provide non-mandatory guidance on how to apply the concept of materiality to accounting policy disclosures. The Group has applied the amendments since 1 January 2023. The amendments did not have any impact on the Group's interim condensed consolidated financial information but are expected to affect the accounting policy disclosures in the Group's annual consolidated financial statements.
- (b) Amendments to HKAS 8 clarify the distinction between changes in accounting estimates and changes in accounting policies. Accounting estimates are defined as monetary amounts in financial statements that are subject to measurement uncertainty. The amendments also clarify how entities use measurement techniques and inputs to develop accounting estimates. The Group has applied the amendments to changes in accounting policies and changes in accounting estimates that occur on or after 1 January 2023. Since the Group's policy of determining accounting estimates aligns with the amendments, the amendments did not have any impact on the financial position or performance of the Group.
- (c) Amendments to HKAS 12 *Deferred Tax related to Assets and Liabilities arising from a Single Transaction* narrow the scope of the initial recognition exception in HKAS 12 so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences, such as leases and decommissioning obligations. Therefore, entities are required to recognise a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability for temporary differences arising from these transactions. Since the Group's policy aligns with the amendments, the amendments did not have any impact on the financial position or performance of the Group.

2. 會計政策及披露事項變動(續)

適用於本集團新訂及經修訂香港財務報告準則的性質及影響闡述如下：

- (a) 香港會計準則第1號(修訂本)要求實體披露其重大會計政策資料而非主要會計政策。倘連同實體財務報表內其他資料一併考慮，會計政策資料可以合理預期會影響通用財務報表的主要使用者根據該等財務報表所作出的決定，則該會計政策資料屬重大。香港財務報告準則實務報告第2號(修訂本)就如何在會計政策之披露中應用重要性概念提供非強制性指引。本集團已自2023年1月1日起應用有關修訂本。該等修訂本對本集團的中期簡明綜合財務資料並無任何影響，惟預期將影響本集團的年度綜合財務報表的會計政策披露。
- (b) 香港會計準則第8號(修訂本)旨在澄清會計估計變動與會計政策變動之間的不同。會計估計的定義為財務報表中涉及計量不確定之貨幣金額。該等修訂本亦解釋實體為作出會計估計而如何使用計量技術及輸入數據。本集團已就於2023年1月1日或之後發生的會計政策變動及會計估計變動應用該等修訂本。由於本集團釐定會計估計的政策與該等修訂本一致，故該等修訂本對本集團的財務狀況或表現並無任何影響。
- (c) 香港會計準則第12號(修訂本)與單一交易產生之資產及負債有關的遞延稅項縮小香港會計準則第12號首次確認例外情況的範圍，使其不再適用於產生相同的應課稅及可扣減暫時性差異的交易(如租賃及棄置義務)。因此，實體須就該等交易產生的暫時性差異確認遞延稅項資產(前提是足夠的應課稅溢利)及遞延稅項負債。由於本集團的政策與該等修訂本一致，故該等修訂本對本集團的財務狀況或表現並無任何影響。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

- (d) Amendments to HKAS 12 International Tax Reform – Pillar Two Model Rules introduce a mandatory temporary exception from the recognition and disclosure of deferred taxes arising from the implementation of the Pillar Two model rules published by the Organisation for Economic Co-operation and Development. The amendments also introduce disclosure requirements for the affected entities to help users of the financial statements better understand the entities' exposure to Pillar Two income taxes, including the disclosure of current tax related to Pillar Two income taxes separately in the periods when Pillar Two legislation is effective and the disclosure of known or reasonably estimable information of their exposure to Pillar Two income taxes in periods in which the legislation is enacted or substantively enacted but not yet in effect. Entities are required to disclose the information relating to their exposure to Pillar Two income taxes in annual periods beginning on or after 1 January 2023, but are not required to disclose such information for any interim periods ending on or before 31 December 2023. The Group has applied the amendments retrospectively. Since the Group did not fall within the scope of the Pillar Two model rules, the amendments did not have any impact to the Group.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

Revenue from contracts with customers 客戶合約收益

2. 會計政策及披露事項變動(續)

- (d) 香港會計準則第12號(修訂本)國際稅收改革 – 支柱二立法模板引入強制性暫時豁免確認及披露實施經濟合作暨發展組織所刊發的支柱二立法模板所產生的遞延稅項。該等修訂本亦為受影響實體引入披露規定，以協助財務報表使用者理解該等實體須繳納的支柱二所得稅，包括分開披露於支柱二法例生效期間有關支柱二所得稅的即期稅項，及披露於法例頒佈或實質上頒佈但尚未生效期間，有關所須繳納的支柱二所得稅的已知或合理可估計資料。實體須於2023年1月1日或之後開始的年度期間披露所須繳納的支柱二所得稅的有關資料，惟毋須於2023年12月31日或之前終止的任何中期期間披露該等資料。本集團已追溯應用有關修訂。由於本集團不屬於支柱二立法模板的規管範圍，故該等修訂對本集團並無任何影響。

3. 經營分部資料

就管理目的而言，本集團並無根據服務劃分各業務單位，故僅有一個可呈報經營分部。管理層會監察本集團整體經營分部的經營業績，以就有關資源分配及表現評估作出決策。

4. 收益、其他收入及收益

收益分析如下：

For the six months
ended 30 June
截至6月30日止六個月

2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
173,506	131,953

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS

(Continued)

Revenue from contracts with customers

(a) Disaggregated revenue information

Type of goods or services

Precision marketing and corporate solutions
Medical knowledge solutions
Intelligent patient management solutions

貨品或服務類型

精準營銷及企業解決方案
醫學知識解決方案
智能患者管理解決方案

Geographical markets

Mainland China
Overseas

地區市場

中國內地
海外

Timing of revenue recognition

Services transferred at a point in time
Services transferred over time

收益確認時間

於某一時間點轉讓的服務
隨時間推移轉讓的服務

(b) Performance obligation

Information about the Group's performance obligation is summarised below:

Application software development service

The performance obligation is satisfied over time as services are rendered or at the point in time when services are accepted according to the agreement. Payment is generally due within 120 days from the date of billing, except for certain customers, where payment in advance is required.

4. 收益、其他收入及收益(續)

客戶合約收益

(a) 分類收益資料

For the six months
ended 30 June
截至6月30日止六個月

	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
	158,097	118,432
	8,062	6,424
	7,347	7,097
	173,506	131,953
	167,421	122,353
	6,085	9,600
	173,506	131,953
	129,518	97,598
	43,988	34,355
	173,506	131,953

(b) 履約責任

有關本集團履約責任的資料概述如下：

應用軟件開發服務

履約責任隨提供服務的時間或根據協議接納服務的時間點達成。一般須自開票之日起120日內支付款項，部分客戶除外，該等客戶需要預付款項。

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS

(Continued)

Revenue from contracts with customers (Continued)

(b) Performance obligation (Continued)

Software licensing service

The performance obligation is satisfied over time as services are rendered and payment in advance is normally required.

Patient counselling service

The performance obligation is satisfied over time as services are rendered and payment is generally due within 120 days from the date of billing.

Other services

The performance obligation is satisfied at a point in time when the individual service is rendered and payment is generally due within 120 days from the date of billing.

An analysis of other income and gains is as follows:

4. 收益、其他收入及收益 (續)

客戶合約收益 (續)

(b) 履約責任 (續)

軟件許可服務

履約責任隨提供服務的時間達成，一般須預付款項。

患者諮詢服務

履約責任隨提供服務的時間達成，且一般須自開票之日起120日內支付款項。

其他服務

履約責任於交付單個服務時達成，且一般須自開票之日起120日內支付款項。

其他收入及收益的分析如下：

For the six months ended 30 June

截至6月30日止六個月

	2023 2023年 RMB'000 (Unaudited) (未經審核)	2022 2022年 RMB'000 (Unaudited) (未經審核)
Bank interest income	82,002	19,514
Government grants*	364	5,476
Investment income from financial assets at fair value through profit or loss	367	384
Others	115	659
	82,848	26,033

* The government grants mainly represent incentives awarded by the local governments to support the Group's operation. There were no unfulfilled conditions or contingencies attached to these grants.

* 政府補貼主要指當地政府授予本集團以支持其運營的獎勵。該等政府補貼概無附帶未達成條件或或然事項。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

Cost of services provided	已提供服務成本
Cost of inventories sold	已售存貨成本
Research and development costs	研發開支
Impairment of trade receivables, net	貿易應收款項減值淨額
Loss on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損
Foreign exchange difference, net	外匯差異，淨額
Equity-settled share award expense	以權益結算的股份獎勵開支

5. 除稅前溢利

本集團之除稅前溢利乃經扣除／(計入)下列各項後達致：

For the six months ended 30 June
截至6月30日止六個月

2023	2022
2023年	2022年
RMB'000	RMB'000
人民幣千元	人民幣千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

68,204	40,669
79	41
18,587	16,844
—	155
—	8
11,764	15,660
6,376	10,629

6. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

The Group calculates the income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim condensed consolidated statement of profit or loss and other comprehensive income are:

6. 所得稅開支

本集團須按實體基準就產生於或來自本集團成員公司註冊及經營所在司法權區的溢利繳納所得稅。

本集團使用適用於預期年度總盈利的稅率計算所得稅開支。中期簡明綜合損益及其他全面收益表中所得稅開支主要組成部分如下：

For the six months ended 30 June
截至6月30日止六個月

2023	2022
2023年	2022年
RMB'000	RMB'000
人民幣千元	人民幣千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Current tax	即期稅項
— Mainland China charge for the period	— 中國內地期間扣除
Deferred tax	遞延稅項
Total tax charge for the period	期間扣除稅項總額

3,693	7,944
(2,689)	(1,718)

1,004	6,226
--------------	-------

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

7. DIVIDENDS

On 9 June 2023, a final dividend for the year ended 31 December 2022 of RMB6.54 cents per ordinary share (2021: RMB1.70 cents), amounting to RMB46,677,648, has been approved by the shareholders at the annual general meeting of the Company. The 2022 final dividend was paid in July 2023.

On 29 August 2023, the board of directors has resolved to declare an interim dividend of RMB10.67 cents per ordinary share (six months ended 30 June 2022: Nil), amounting to a total of approximately RMB77,580,000 (six months ended 30 June 2022: Nil).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 717,912,514 (2022: 713,225,500) in issue during the period. The number of shares for the current period has been arrived at after eliminating the shares held under the share award scheme.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

7. 股息

於2023年6月9日，本公司股東已於股東週年大會批准派發截至2022年12月31日止年度的末期股息每股普通股人民幣6.54分(2021年：人民幣1.70分)，合計金額人民幣46,677,648元。2022年末期股息已於2023年7月派發。

於2023年8月29日，董事會決議宣佈派發中期股息每股普通股人民幣10.67分(截至2022年6月30日止六個月：無)，合共約人民幣77,580,000元(截至2022年6月30日止六個月：無)。

8. 母公司普通權益持有人應佔每股盈利

每股基本盈利按期內母公司普通股持有人應佔溢利及已發行普通股加權平均數717,912,514股(2022年：713,225,500股)計算。本期股份數量是在剔除根據股份獎勵計劃持有的股份後得出的。

每股攤薄盈利按母公司普通股持有人應佔期間溢利計算。計算所用之普通股加權平均數為計算每股基本盈利所用之普通股數目以及假設視為行使或轉換所有具攤薄潛力普通股為普通股時無償發行之普通股加權平均數。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Continued)

The calculations of basic and diluted earnings per share are based on:

8. 母公司普通權益持有人應佔每股盈利(續)

每股基本及攤薄盈利之計算乃基於：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
<u>Earnings</u>	<u>盈利</u>		
Profit attributable to ordinary equity holders of the parent	母公司普通股持有人應佔溢利	98,718	26,973
		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核)	2022 2022年 (Unaudited) (未經審核)
<u>Shares</u>	<u>股份</u>		
Weighted average number of ordinary shares in issue used in the basic earnings per share calculation	計算每股基本盈利所用之已發行普通股加權平均數	717,912,514	713,225,500
Effect of dilution — weighted average number of ordinary shares arising from share options	攤薄影響 — 源自購股權的普通股加權平均數	19,151,527	25,650,856
		737,064,041	738,876,356

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

9. TRADE RECEIVABLES

Trade receivables	貿易應收款項
Impairment	減值

The Group's trading terms with its customers are mainly on credit. The credit terms granted generally ranged up to 180 days, depending on the specific payment terms in each contract. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

Within 6 months	少於六個月
6 to 12 months	六至十二個月
1 to 2 years	一至兩年
2 to 3 years	兩至三年

9. 貿易應收款項

30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
---	---

92,576	95,893
(1,001)	(814)

91,575	95,079
---------------	--------

本集團與客戶之間的貿易條款以信貸為主。一般授予最多180天的信貸期，視各個合約的具體付款條件而定。本集團致力於維持對未償還應收款項之嚴格控制。逾期結餘由高級管理層定期審閱。本集團並無就貿易應收款項結餘持有任何抵押品或其他信用提升物品。貿易應收款項不計利息。

於報告期間末按發票日期呈列並經扣除虧損撥備的貿易應收款項的賬齡分析如下：

30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
---	---

88,927	94,533
2,380	131
219	397
49	18

91,575	95,079
---------------	--------

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

10. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

Within 3 months	少於三個月
3 to 6 months	三至六個月
6 to 12 months	六至十二個月
Over 1 year	超過一年

Included in the Group's trade payables were amounts due to M3, Inc., a shareholder of the Company of RMB582,000 (31 December 2022: RMB276,000), which are repayable on demand.

The trade payables are non-interest-bearing and are normally settled within one year.

10. 貿易應付款項

於報告期間末，基於發票日期的貿易應付款項的賬齡分析如下：

30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
2,879	2,516
472	82
281	89
47	22
3,679	2,709

本集團貿易應付款項內包括本公司股東 M3, Inc. 結欠款項人民幣 582,000 元 (2022 年 12 月 31 日：人民幣 276,000 元)，該款項須按要求還款。

貿易應付款項不計息且一般於一年內結算。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

11. SHARE CAPITAL

11. 股本

	30 June 2023 2023年 6月30日 US\$ 美元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 US\$ 美元 (Audited) (經審核)
Authorised: 50,000,000,000 ordinary shares of US\$0.00001 each	法定： 50,000,000,000股 普通股每股面值 0.00001美元	500,000
Issued and fully paid: 720,334,000 (2022: 717,348,000) ordinary shares of US\$0.00001 each	已發行及繳足： 720,334,000 (2022年： 717,348,000)股普通 股每股面值0.00001 美元	7,203
Equivalent to RMB	相當於人民幣	45,000

On 21 January 2022, the Company issued 500,000 ordinary shares with par value of US\$0.00001 each pursuant to the share award scheme of the Company adopted by the board of directors with effect from 24 December 2021.

於2022年1月21日，本公司根據經董事會採納自2021年12月24日生效的本公司股份獎勵計劃，發行500,000股每股面值0.00001美元的普通股。

In July and October 2022, the Company issued 1,867,500 and 1,755,000 ordinary shares with par value of US\$0.00001 each, respectively, for the exercise of share options under the Company's share option scheme.

於2022年7月及10月，本公司就行使本公司購股權計劃的購股權分別發行1,867,500股及1,755,000股每股面值0.00001美元的普通股。

In April and May 2023, the Company issued 2,441,000 and 545,000 ordinary shares with par value of US\$0.00001 each, respectively, for the exercise of share options under the Company's share option scheme.

於2023年4月及5月，本公司就行使本公司購股權計劃的購股權分別發行2,441,000股及545,000股每股面值0.00001美元的普通股。

12. BUSINESS COMBINATION

On 12 June 2023, the Group entered into an equity transfer agreement with Beijing SCMedcon Co., Ltd. (“SCMedcon”) and its then shareholders (the “Sellers”), pursuant to which the Group agreed to acquire 50% equity interests in SCMedcon from its then shareholders at a cash consideration of RMB65,000,000.

SCMedcon is principally engaged in the business of organising medical exhibition conferences and exchange meetings for pharmaceutical and medical devices companies and institutions serving the medical industry, and provision of related medical training services and medical content services. Utilising the expertise of its employees, SCMedcon is also engaged in the provision of a comprehensive range of management consulting and medical technology services to pharmaceutical and medical devices companies such as the production of medical knowledge materials and medical data management and analysis. The acquisition was made as part of the Group’s business strategy to achieve external growth by strategically pursuing partnership and acquisition opportunities. The acquisition was completed on 12 June 2023 when the Group obtained control of the operating and financial activities of SCMedcon. SCMedcon has become an indirect non-wholly-owned subsidiary of the Group. The Consideration shall be paid in cash at a maximum of five instalments, with RMB35,750,000 paid at the acquisition date and the remaining four installments shall be paid in 2023, 2024, 2025 and 2026 (“Guaranteed periods”). The purchase consideration will be adjusted downwards if SCMedcon’s net profit for the guaranteed periods does not reach the agreed guaranteed profit. For the details of the acquisition information, please refer to the Company’s announcement dated 12 June 2023.

As stipulated in the equity transfer agreement, the Sellers of SCMedcon have granted the option to the Group so that if the actual cumulative net profit of SCMedcon for all the guaranteed periods does not reach 55% of the guaranteed profit for the guaranteed periods, the Group has the right, but not an obligation, to require the Sellers to repurchase SCMedcon’s equity held by the Group. As at 30 June 2023, the Group expected not to exercise the option and the value of the option was assessed to be minimal.

The Group has elected to measure the non-controlling interest in SCMedcon at the non-controlling interest’s proportionate share of the SCMedcon’s identifiable net assets.

12. 業務合併

於2023年6月12日，本集團與北京石成醫學諮詢有限公司（「石成醫學」）及其當時的股東（「賣方」）訂立股權轉讓協議，據此，本集團同意按現金代價人民幣65,000,000元自石成醫學當時的股東收購其50%股權。

石成醫學主要從事為製藥及醫療器械公司及服務於醫療行業的機構組織醫療展會及交流會，並提供相關醫學培訓服務及醫學內容服務。利用其僱員的專業知識，石成醫學亦從事為製藥及醫療器械公司提供全面的管理諮詢和醫學技術服務，例如製作醫學知識材料及醫學數據管理及分析。此次收購乃本集團業務戰略的一部分，旨在通過戰略性地尋求合作和收購機會，實現外部增長。此次收購於2023年6月12日完成，屆時本集團獲得石成醫學經營及財務活動的控制權。石成醫學成為本集團間接非全資附屬公司。代價應以現金支付，最多分五期支付，其中人民幣35,750,000元於收購日支付，其餘四期應於2023年、2024年、2025年及2026年（「保證期」）支付。倘石成醫學於保證期的淨溢利未達到約定的保證溢利，則購買代價將下調。有關收購資料的詳情，請參閱本公司2023年6月12日的公告。

按股權轉讓協議規定，石成醫學的賣方授予本集團期權，倘若石成醫學於所有保證期的實際累計淨溢利未達到保證期的保證溢利55%，則本集團有權但並非責任要求賣方購回本集團所持石成醫學股權。於2023年6月30日，本集團預期不行使期權，而期權價值評估為甚小。

本集團選擇將所持石成醫學非控股權益按非控股權益應佔石成醫學可識別淨資產計量。

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

12. BUSINESS COMBINATION (Continued)

The fair values of the identifiable assets and liabilities of SCMedcon as at the date of acquisition were as follows:

		Fair value recognised on acquisition 於收購時確認的 公允價值 RMB'000 人民幣千元 (Unaudited) (未經審核)
Property, plant and equipment	物業、廠房及設備	42
Deferred tax assets	遞延稅項資產	47
Trade receivables	貿易應收款項	3,492
Contract assets	合約資產	1,764
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	3,106
Financial assets at fair value through profit or loss	按公允價值計量且其變動計入損益的金融資產	6,410
Cash and cash equivalents	現金及現金等價物	5,436
Trade payables	貿易應付款項	(818)
Other payables and accruals	其他應付款項及應計費用	(3,025)
Tax payable	應付稅項	(1,582)
Dividend payable	應付股息	(3,200)
Total identifiable net assets at fair value	按公允價值可識別資產淨值總額	11,672
Non-controlling interests	非控股權益	(5,836)
Goodwill on acquisition	收購時的商譽	59,164
<u>Satisfied by:</u>	<u>以下列方式支付:</u>	
Cash consideration paid as at 30 June 2023	截至2023年6月30日已付的現金代價	35,750
Contingent consideration liability as at 30 June 2023	截至2023年6月30日的或然代價負債	29,250
Total consideration	代價總額	65,000

The fair values of the trade receivables and other receivables as at the date of acquisition amounted to RMB3,492,000 and RMB3,011,000, respectively. The gross contractual amounts of trade receivables and other receivables were RMB3,679,000 and RMB3,011,000, of which trade receivables of RMB187,000 are expected to be uncollectible.

12. 業務合併(續)

石成醫學於收購日可識別資產及負債的公允價值如下:

		Fair value recognised on acquisition 於收購時確認的 公允價值 RMB'000 人民幣千元 (Unaudited) (未經審核)
Property, plant and equipment	物業、廠房及設備	42
Deferred tax assets	遞延稅項資產	47
Trade receivables	貿易應收款項	3,492
Contract assets	合約資產	1,764
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	3,106
Financial assets at fair value through profit or loss	按公允價值計量且其變動計入損益的金融資產	6,410
Cash and cash equivalents	現金及現金等價物	5,436
Trade payables	貿易應付款項	(818)
Other payables and accruals	其他應付款項及應計費用	(3,025)
Tax payable	應付稅項	(1,582)
Dividend payable	應付股息	(3,200)
Total identifiable net assets at fair value	按公允價值可識別資產淨值總額	11,672
Non-controlling interests	非控股權益	(5,836)
Goodwill on acquisition	收購時的商譽	59,164
<u>Satisfied by:</u>	<u>以下列方式支付:</u>	
Cash consideration paid as at 30 June 2023	截至2023年6月30日已付的現金代價	35,750
Contingent consideration liability as at 30 June 2023	截至2023年6月30日的或然代價負債	29,250
Total consideration	代價總額	65,000

於收購日的貿易應收款項及其他應收款項的公允價值分別為人民幣3,492,000元及人民幣3,011,000元。貿易應收款項及其他應收款項的合同款項總額為人民幣3,679,000元及人民幣3,011,000元，其中貿易應收款項人民幣187,000元預期不可收回。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

12. BUSINESS COMBINATION (Continued)

The Group incurred transaction costs of RMB100,000 for this acquisition. These transaction costs have been expensed and are included in administrative expenses in the interim condensed consolidated statement of profit or loss and other comprehensive income.

The goodwill of RMB59,164,000 recognised above is due to the brand awareness and the value of expected synergies. The above factor is neither separable nor contractual and therefore it does not meet the criteria for recognition as intangible assets under HKAS 38 *Intangible Assets*. None of the goodwill recognised is expected to be deductible for income tax purposes.

Since the acquisition, SCMedcon contributed RMB1,690,000 to the Group's revenue and RMB128,000 to the consolidated profit for the six months ended 30 June 2023.

Had the combination taken place at the beginning of the period, the revenue from continuing operations of the Group and the profit of the Group for the period would have been RMB19,673,000 and RMB3,709,000, respectively.

The assessment of the fair value of the identifiable assets and liabilities of SCMedcon is still undergoing and the information of the fair values of the identifiable assets and liabilities and contingent consideration is provisional at the date of the interim condensed consolidated financial information. The finalised information will be disclosed in the consolidated financial statements of the Group for the year ending 31 December 2023.

An analysis of the cash flows in respect of the acquisition of a subsidiary is as follows:

12. 業務合併(續)

本集團就收購事項產生人民幣100,000元的交易成本。該等交易成本已列支，並計入中期簡明綜合損益及其他全面收益表的行政開支內。

上述已確認人民幣59,164,000元的商譽乃由於品牌知名度及預期協同效益價值。上述因素並非獨立或合約性質，因此根據香港會計準則第38號無形資產，並不符合確認為無形資產的準則。概無已確認商譽預期就所得稅目的而可予扣減。

自收購以來，石成醫學於截至2023年6月30日止六個月向本集團收入貢獻人民幣1,690,000元及綜合溢利貢獻人民幣128,000元。

倘合併於期初發生，期內本集團持續經營的收益及本集團的溢利將分別為人民幣19,673,000元及人民幣3,709,000元。

石成醫學的可識別資產及負債的公允價值評估仍在進行，而於中期簡明綜合財務資料日期的可識別資產及負債的公允價值以及或然代價資料為暫定。最終資料將於本集團截至2023年12月31日止年度之綜合財務報表披露。

收購附屬公司的現金流量分析如下：

		RMB'000 人民幣千元 (Unaudited) (未經審核)
Cash consideration	現金代價	(35,750)
Cash and bank balances acquired	已獲得現金及銀行結餘	5,436
Net outflow of cash and cash equivalents included in cash flows from investing activities	計入投資活動所得現金流量的現金及現金等價物流出淨額	(30,314)
Transaction costs of the acquisition included in cash flows from operating activities	計入經營活動所得現金流量的收購交易成本	(100)
		(30,414)

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

13. COMMITMENTS

At the end of the reporting period, the Group did not have any significant commitments.

14. RELATED PARTY TRANSACTIONS

Details of the Group's related parties are as follows:

Company

本公司

Tiantian Co., Limited (“**Tiantian**”)
Tiantian Co., Limited (「**Tiantian**」)

M3, Inc.
M3, Inc.

M3 USA Corporation (“**M3 USA**”)
M3 USA Corporation (「**M3 USA**」)

M3 (EU) Limited (“**M3 (EU)**”)
M3 (EU) Limited (「**M3 (EU)**」)

M Panels Research Services PVT Ltd. (“**M Panels**”)
M Panels Research Services PVT Ltd. (「**M Panels**」)

Qualitative and Quantitative Fieldwork Service AB (“**QQFS**”)
Qualitative and Quantitative Fieldwork Service AB (「**QQFS**」)

Liwen Bianji Co., Limited (“**Liwen Bianji**”)
北京精銳理文文化傳播有限公司(「**精銳理文**」)

Beijing Jinye Tiansheng Technology Co., Ltd. (“**Jinye Tiansheng**”)
北京金葉天盛科技有限公司(「**金葉天盛**」)

Yunnan Medcon Information Technology Co., Ltd. (“**Yunnan Medcon**”)
雲南美迪康信息技術有限公司(「**雲南美迪康**」)

13. 承擔

於報告期末，本集團概無任何重大承擔。

14. 關聯方交易

本集團關聯方詳情如下：

Relationship with the Company

與本公司的關係

Shareholder of the Company
本公司股東

Shareholder of the Company
本公司股東

Entity controlled by M3, Inc.
M3, Inc. 控股實體

Entity controlled by M3, Inc.
M3, Inc. 控股實體

Entity controlled by M3, Inc.
M3, Inc. 控股實體

Entity controlled by M3, Inc.
M3, Inc. 控股實體

Entity controlled by M3, Inc.
M3, Inc. 控股實體

Entity controlled by a director
董事控股實體

Associate

聯營公司

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

14. RELATED PARTY TRANSACTIONS (Continued)

- (a) In addition to the transactions detailed elsewhere in this financial information, the Group had the following transactions with related parties during the six months ended 30 June 2023 and 2022:

14. 關聯方交易(續)

- (a) 除本財務資料其他部分詳述的交易外，本集團截至2023年及2022年6月30日止六個月與關聯方進行的交易如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
		<i>Notes 附註</i>	
Precision marketing and corporate solutions provided to:	精準營銷及企業解決方案提供予：		
M3 USA	M3 USA	<i>(i)</i>	3,831
M3 (EU)	M3 (EU)	<i>(i)</i>	1,730
M Panels	M Panels	<i>(i)</i>	303
QQFS	QQFS	<i>(i)</i>	487
M3, Inc.	M3, Inc.	<i>(i)</i>	38
			5,381
Intelligent patient management solutions provided to:	智能患者管理解決方案提供予：		
M3 USA	M3 USA	<i>(i)</i>	149
M3, Inc.	M3, Inc.	<i>(i)</i>	25
M3 (EU)	M3 (EU)	<i>(i)</i>	15
			—
Software licensing fee to:	軟件許可費予：		
M3 USA	M3 USA	<i>(ii)</i>	70
License and service fee to:	許可及服務費予：		
M3, Inc.	M3, Inc.	<i>(iii)</i>	268
Editing service fee to:	編輯服務費予：		
Liwen Bianji	精銳理文	<i>(iv)</i>	3

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

14. RELATED PARTY TRANSACTIONS (Continued)

(a) (Continued)

Notes:

- (i) The service fees were determined on normal commercial terms, negotiated on arm's length basis, on similar basis as the Group conducted businesses with other independent third parties.
- (ii) The software licensing fee to M3 USA was made according to the published prices and conditions offered by the related party to its major customers.
- (iii) The license and service fees were determined on the basis of arm's length negotiations between the parties.
- (iv) The editing service fee were determined on the basis of arm's length negotiations between the parties.

(b) Outstanding balances with related parties:

Contract assets	合約資產	
M3 USA	M3 USA	2,276
M3 (EU)	M3 (EU)	888
QQFS	QQFS	178
M Panels	M Panels	558
M3, Inc.	M3, Inc.	—
		3,900
Trade payables	貿易應付款項	
M3, Inc.	M3, Inc.	582
Other payables	其他應付款項	
Yunnan Medcon	雲南美迪康	280

Except for the amount due to Yunnan Medcon, the outstanding balances with related parties were all trade in nature.

14. 關聯方交易(續)

(a) (續)

附註：

- (i) 服務費按一般商業條款經公平磋商而釐定，相關基準與本集團與其他獨立第三方進行業務相近。
- (ii) 向M3 USA支付的軟件許可費乃根據已公佈的價格及關聯方向其主要客戶提供的條件釐定。
- (iii) 許可及服務費乃經雙方公平磋商釐定。
- (iv) 編輯服務費乃經雙方公平磋商釐定。

(b) 與關聯方的未結算結餘：

30 June	31 December
2023	2022
2023年	2022年
6月30日	12月31日
RMB'000	RMB'000
人民幣千元	人民幣千元
(Unaudited)	(Audited)
(未經審核)	(經審核)

	3,900	6,045
	582	276
	280	280

除應付予雲南美迪康的款項外，與關聯方的未結算結餘均為貿易性質。

Notes to Unaudited Interim Condensed Consolidated Financial Information

未經審核中期簡明綜合財務資料附註

14. RELATED PARTY TRANSACTIONS (Continued)

- (c) Compensation of key management personnel of the Group:

Salaries, allowances and benefits in kind	薪金、津貼及實物福利
Pension scheme contributions	退休金計劃供款
Equity-settled share award expense	以權益結算的股份獎勵開支
Total compensation paid to key management personnel	支付主要管理層人員的薪酬總額

14. 關聯方交易(續)

- (c) 本集團主要管理層人員薪酬：

For the six months ended 30 June
截至6月30日止六個月

2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
2,834	2,418
217	189
4,022	7,478
7,073	10,085

15. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at 30 June 2023 and 31 December 2022 are as follows:

Financial assets at amortised cost

Trade receivables	貿易應收款項
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產
Time deposits	定期存款
Cash and cash equivalents	現金及現金等價物

15. 按類別劃分的金融工具

於2023年6月30日及2022年12月31日，各類別金融工具之賬面值如下：

按攤銷成本計量的金融資產

30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
91,575	95,079
6,499	4,657
93,966	92,438
4,373,272	4,187,264
4,565,312	4,379,438

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

15. FINANCIAL INSTRUMENTS BY CATEGORY

(Continued)

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss

Financial liabilities at amortised cost

Trade payables

Financial liabilities included in other payables and accruals

Financial liabilities at fair value through profit or loss

Contingent consideration payables

按公允價值計量且其變動計入損益的金融資產

貿易應付款項
計入其他應收款項及應計費用的金融負債

應付或然代價

15. 按類別劃分的金融工具(續)

按公允價值計量且其變動計入損益的金融資產

按攤餘成本計量的金融負債

按公允價值計量且其變動計入損益的金融負債

30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
39,650	29,640
<hr/>	
3,679	2,709
38,375	12,009
<hr/>	
42,054	14,718
<hr/>	
60,989	41,759

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, trade receivables, trade payables, financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals and the current portion of lease liabilities approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of the non-current portion of lease liabilities has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group's own non-performance risk for lease liabilities as at the end of the reporting period was assessed to be insignificant.

The Group invests in unlisted investments, which represent certain financial products issued by commercial banks in Mainland China. The Group has estimated the fair value of these unlisted investments by using the valuation technique based on the sum of principal and interest receivable.

The fair value of the contingent consideration payables has been estimated using Monte Carlo simulation valuation technique based on assumptions that are not supported by observable market prices or rates. The valuation requires management to calculate some appropriate inputs, such as discount rate. Management believes that the estimated fair value resulting from the valuation technique, which is recorded in the consolidated statement of financial position, and the related change in fair values, which is recorded in profit or loss, are reasonable, and that it was the most appropriate value at the end of the period.

16. 金融工具的公允價值及公允價值等級

管理層已評估，現金和現金等價物、貿易應收款項、貿易應付款項、計入預付款項、其他應收款項及其他資產的金融資產、計入其他應付款項和應計費用的金融負債、租賃負債的即期部分的公允價值均與其賬面值相若，主要是由於該等工具於短期內到期。

金融資產和負債的公允價值按自願方於一項現行交易(強迫或清盤出售除外)中交換有關工具的金額列值。

租賃負債的非即期部分的公允價值已使用具有類似條款、信貸風險及餘下到期日的工具現時可取得的利率貼現預期未來現金流量而計算。本集團於報告期末就租賃負債的自身不履約風險導致的公允價值變動被評定為微不足道。

本集團投資於非上市投資，即中國內地商業銀行發行的若干金融產品。本集團已使用基於應收本金及利息之和的估值技術估算該等非上市投資的公允價值。

應付或然代價的公允價值基於無可觀察市場價格或利率支持的假設，使用蒙特卡羅模擬估值技術釐定。估值要求管理層計算部分適當的輸入數據，例如貼現率。管理層認為估值技術得出的估計公允價值(計入綜合財務狀況表)及相關公允價值變動(計入損益)合理，且認為是期末最適當的價值。

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Below is a summary of significant unobservable inputs to the valuation of financial liabilities together with a quantitative sensitivity analysis as at 30 June 2023 and 31 December 2022:

	Valuation technique 估值技術	Significant unobservable inputs 重要不可觀察輸入數據	Rate 利率	Sensitivity of fair value to the input 公允價值對輸入數據的敏感程度
Contingent consideration payables 應付或然代價	Monte Carlo simulation 蒙特卡羅模擬	Discount rate 貼現率	3.65%-3.84% (31 December 2022: 3.65%-3.84%) 3.65%-3.84% (2022年12月31日: 3.65%-3.84%)	5% (31 December 2022:5%) increase/decrease in discount rate would result in decrease/increase in fair value by 0.2% (31 December 2022: 0.2%) 貼現率增/減5% (2022年12月31日: 5%) 導致公允價值減/增0.2% (2022年12月31日: 0.2%)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2023

16. 金融工具的公允價值及公允價值等級 (續)

下文金融負債估值的重要不可觀察輸入數據與2023年6月30日及2022年12月31日的量化敏感性分析概要：

公允價值等級

下表列明本集團金融工具的公允價值計量等級：

按公允價值計量的資產：

於2023年6月30日

Fair value measurement using 公允價值計量採用

	Quoted prices in active markets 於活躍市場的報價 (Level 1) (第一級) RMB'000 人民幣千元 (Unaudited) (未經審核)	Significant observable inputs 重大可觀察輸入數據 (Level 2) (第二級) RMB'000 人民幣千元 (Unaudited) (未經審核)	Significant unobservable inputs 重大不可觀察輸入數據 (Level 3) (第三級) RMB'000 人民幣千元 (Unaudited) (未經審核)	Total 總計 RMB'000 人民幣千元 (Unaudited) (未經審核)
Financial assets at fair value through profit or loss 按公允價值計量且其變動計入損益的金融資產	-	39,650	-	39,650

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

As at 31 December 2022

16. 金融工具的公允價值及公允價值等級 (續)

公允價值等級 (續)

按公允價值計量的資產：(續)

於2022年12月31日

	Fair value measurement using 公允價值計量採用			Total 總計
	Quoted prices in active markets 於活躍 市場的報價 (Level 1) (第一級) RMB'000 人民幣千元 (Audited) (經審核)	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第二級) RMB'000 人民幣千元 (Audited) (經審核)	Significant unobservable inputs 重大不可觀察 輸入數據 (Level 3) (第三級) RMB'000 人民幣千元 (Audited) (經審核)	
Financial assets at fair value through profit or loss	—	29,640	—	29,640

按公允價值計量且其變動計入損益的金融資產

Liabilities measured at fair value:

As at 30 June 2023

按公允價值計量的負債：

於2023年6月30日

	Fair value measurement using 公允價值計量採用			Total 總計
	Quoted prices in active markets 於活躍 市場的報價 (Level 1) (第一級) RMB'000 人民幣千元 (Unaudited) (未經審核)	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第二級) RMB'000 人民幣千元 (Unaudited) (未經審核)	Significant unobservable inputs 重大不可觀察 輸入數據 (Level 3) (第三級) RMB'000 人民幣千元 (Unaudited) (未經審核)	
Contingent consideration payables	—	—	60,989	60,989

應付或然代價

Notes to Unaudited Interim Condensed Consolidated Financial Information 未經審核中期簡明綜合財務資料附註

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value: (Continued)

As at 31 December 2022

16. 金融工具的公允價值及公允價值等級 (續)

公允價值等級 (續)

按公允價值計量的負債：(續)

於2022年12月31日

	Fair value measurement using 公允價值計量採用			Total 總計
	Quoted prices in active markets 於活躍 市場的報價 (Level 1) (第一級) RMB'000 人民幣千元 (Audited) (經審核)	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第二級) RMB'000 人民幣千元 (Audited) (經審核)	Significant unobservable inputs 重大不可觀察 輸入數據 (Level 3) (第三級) RMB'000 人民幣千元 (Audited) (經審核)	
Contingent consideration payables	—	—	41,759	41,759
				<i>RMB'000</i> 人民幣千元 (Audited) (經審核)

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (six months ended 30 June 2022: Nil).

期內，金融資產及金融負債均無第一級與第二級之間的公允價值計量轉撥，亦無轉入第三級或自第三級轉出(截至2022年6月30日止六個月：無)。

17. EVENTS AFTER THE REPORTING PERIOD

The Company and its subsidiaries have no significant subsequent events need to be disclosed.

17. 報告期後事項

本公司及其附屬公司並無重大期後事項需要披露。

18. APPROVAL OF THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

The unaudited interim condensed consolidated financial information was approved and authorised for issue by the board of directors on 29 August 2023.

18. 批准未經審核中期簡明綜合財務資料

未經審核中期簡明綜合財務資料由董事會於2023年8月29日批准及授權刊發。

Other Information 其他資料

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2023, the interests and short positions of the Directors or the chief executive of the Company in the Shares, underlying Shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO) or which would be recorded in the register required to be kept by the Company pursuant to section 352 of the SFO or as notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) were as follows:

(i) INTERESTS OF DIRECTORS AND CHIEF EXECUTIVE OF THE COMPANY

**Name of Director/
Chief Executive**
董事/
最高行政人員姓名

Nature of interest

權益性質

Ms. Tian Liping⁽²⁾⁽³⁾
田立平女士⁽²⁾⁽³⁾

Interest in controlled corporation
受控法團權益
Beneficial interest
實益權益
Interest of spouse
配偶權益

**Number of
underlying
Shares**
相關股份數目

**Approximate
percentage of
shareholding
interest**
概約股權百分比

267,540,000 37.14%
10,494,500 1.46%
100,000 0.01%

Mr. Tian Lixin⁽²⁾⁽⁴⁾
田立新先生⁽²⁾⁽⁴⁾

Interest in controlled corporation
受控法團權益
Beneficial interest
實益權益
Interest of spouse
配偶權益

267,540,000 37.14%
2,550,000 0.35%
100,000 0.01%

Mr. Tian Lijun⁽²⁾⁽⁵⁾
田立軍先生⁽²⁾⁽⁵⁾

Beneficial interest
實益權益

2,200,000 0.31%

董事及最高行政人員於股份、相關股份及債權證的權益及淡倉

於2023年6月30日，董事或本公司最高行政人員於本公司及其相聯法團(定義見《證券及期貨條例》(《證券及期貨條例》))第XV部的股份、相關股份或債權證中擁有根據《證券及期貨條例》第XV部第7及第8分部須知會本公司及聯交所的權益或淡倉(包括根據《證券及期貨條例》的有關條文當作或被視為擁有的權益或淡倉)，或根據《證券及期貨條例》第352條須記錄於本公司保存的登記冊的權益及淡倉，或根據上市發行人董事進行證券交易的標準守則(《標準守則》)須知會本公司及聯交所的權益及淡倉如下：

(i) 本公司董事及最高行政人員所持權益

Notes:

- (1) All interests stated are long positions.
- (2) Ms. Tian Liping, Mr. Tian Lixin and Mr. Tian Lijun are brothers and sister of each other. Tiantian Co., Limited is held as to 48%, 37% and 15% by Ms. Tian Liping, Mr. Tian Lixin and Mr. Tian Lijun, respectively. Tiantian Co., Limited directly holds 267,540,000 Shares, and Ms. Tian Liping and Mr. Tian Lixin are deemed to be interested in the 267,540,000 Shares held by Tiantian Co., Limited.
- (3) Ms. Tian Liping is interested in 2,891,000 Shares and Pre-IPO Share Options to subscribe for 7,603,500 Shares. Ms. Tian Liping is deemed to be interested in the 25,000 Shares and Pre-IPO Share Options to subscribe for 75,000 Shares held by her spouse, Mr. Zhang Xiaofeng.
- (4) Mr. Tian Lixin is interested in 637,500 Shares and Pre-IPO Share Options to subscribe for 1,912,500 Shares. Mr. Tian Lixin is deemed to be interested in the 25,000 Shares and Pre-IPO Share Options to subscribe for 75,000 Shares held by his spouse, Ms. Liu Lingdi.
- (5) Mr. Tian Lijun is interested in 287,500 Shares and Pre-IPO Share Options to subscribe for 1,912,500 Shares.
- (6) As at 30 June 2023, the total number of issued Shares was 720,334,000.

附註：

- (1) 所有權益均為好倉。
- (2) 田立平女士、田立新先生及田立軍先生為胞兄弟姊妹。Tiantian Co., Limited分別由田立平女士、田立新先生及田立軍先生擁有48%、37%及15%權益。Tiantian Co., Limited直接擁有267,540,000股股份，田立平女士及田立新先生視為擁有Tiantian Co., Limited所持267,540,000股股份的權益。
- (3) 田立平女士於2,891,000股股份及可認購7,603,500股股份的首次公開發售前購股權擁有權益。田立平女士視為於張曉峰先生(田立平女士之配偶)持有之25,000股股份及可認購75,000股股份的首次公開發售前購股權中擁有權益。
- (4) 田立新先生於637,500股股份及可認購1,912,500股股份的首次公開發售前購股權擁有權益。田立新先生視為於劉領娣女士(田立新先生之配偶)持有之25,000股股份及可認購75,000股股份的首次公開發售前購股權中擁有權益。
- (5) 田立軍先生於287,500股股份及可認購1,912,500股股份的首次公開發售前購股權中擁有權益。
- (6) 於2023年6月30日，已發行股份總數為720,334,000股股份。

(ii) INTEREST IN THE COMPANY'S SUBSIDIARY,
BEIJING YIMAIHUTONG TECHNOLOGY CO., LTD.

Name of Director/ Chief Executive 董事／ 最高行政人員姓名	Nature of interest 權益性質
---	----------------------------

Ms. Tian Liping 田立平女士	Beneficial owner 實益擁有人
--------------------------	---------------------------

Mr. Tian Lixin 田立新先生	Beneficial owner 實益擁有人
-------------------------	---------------------------

Save as disclosed above, so far as the Directors were aware, as at 30 June 2023, no persons (excluding the Company) were directly or indirectly interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of the Group.

(ii) 於本公司附屬公司北京醫脈互通科技
技術有限公司的權益

Registered capital 註冊資本	Percentage of interest 權益百分比
RMB5,000,000 registered capital 註冊資本 人民幣5,000,000元	50%
RMB5,000,000 registered capital 註冊資本 人民幣5,000,000元	50%

除上文所披露者外，就董事所知，於2023年6月30日，概無人士(不包括本公司)直接或間接擁有附帶權利可於任何情況下在本集團任何其他成員公司股東大會上投票的任何類別股本面值10%或以上的權益。

Other Information 其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2023, so far as is known to the Directors, the following persons (other than the Directors or chief executive of the Company) had interests or short positions in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which would be recorded in the register required to be kept under Section 336 of the SFO:

主要股東於股份及相關股份的權益及淡倉

於2023年6月30日，就董事所知，下列人士（董事或本公司最高行政人員除外）於股份或相關股份中擁有根據《證券及期貨條例》第XV部第2及3分部條文須向本公司披露的權益或淡倉，或須登記在根據《證券及期貨條例》第336條規定設立的登記冊的權益或淡倉：

Name 姓名／名稱	Nature of interest 權益性質	Number of underlying Shares 相關股份數目	Approximate percentage of shareholding interest 概約股權百分比
Mr. Zhang Xiaofeng 張曉峰先生	Interest of spouse ⁽²⁾ 配偶權益 ⁽²⁾	267,540,000	37.14%
	Interest of spouse ⁽²⁾ 配偶權益 ⁽²⁾	10,494,500	1.46%
	Beneficial interest ⁽³⁾ 實益權益 ⁽³⁾	100,000	0.01%
Ms. Liu Lingdi 劉領娣女士	Interest of spouse ⁽⁴⁾ 配偶權益 ⁽⁴⁾	267,540,000	37.14%
	Interest of spouse ⁽⁴⁾ 配偶權益 ⁽⁴⁾	2,550,000	0.35%
	Beneficial interest ⁽⁵⁾ 實益權益 ⁽⁵⁾	100,000	0.01%
Tiantian Co., Limited ⁽⁶⁾	Beneficial owner 實益擁有人	267,540,000	37.14%
M3, Inc. ⁽⁷⁾	Beneficial owner 實益擁有人	267,540,000	37.14%
Sony Group Corporation ⁽⁷⁾	Interest in controlled corporation 受控法團權益	267,540,000	37.14%
FIL Limited ⁽⁸⁾	Interest in controlled corporation 受控法團權益	64,986,433	9.02%
Pandanus Partners L.P. ⁽⁸⁾	Interest in controlled corporation 受控法團權益	64,986,433	9.02%
Pandanus Associates Inc. ⁽⁸⁾	Interest in controlled corporation 受控法團權益	64,986,433	9.02%

Notes:

- (1) All interests stated are long positions.
- (2) Mr. Zhang Xiaofeng is the spouse of Ms. Tian Liping. Mr. Zhang Xiaofeng is deemed to be interested in 267,540,000 Shares held by Tiantian Co., Limited in which Ms. Tian Liping is interested as well as the 2,891,000 Shares and the Pre-IPO Share Options to subscribe for 7,603,500 Shares held by Ms. Tian Liping.
- (3) Includes 25,000 Shares and Pre-IPO Share Options to subscribe for 75,000 Shares held by Mr. Zhang Xiaofeng.
- (4) Ms. Liu Lingdi is the spouse of Mr. Tian Lixin. Ms. Liu Lingdi is deemed to be interested in 267,540,000 Shares held by Tiantian Co., Limited in which Mr. Tian Lixin is interested as well as the 637,500 Shares and the Pre-IPO Share Options to subscribe for 1,912,500 Shares held by Mr. Tian Lixin.
- (5) Includes 25,000 Shares and Pre-IPO Share Options to subscribe for 75,000 Shares held by Ms. Liu Lingdi.
- (6) Tiantian Co., Limited is held as to 48%, 37% and 15% by Ms. Tian Liping, Mr. Tian Lixin and Mr. Tian Lijun, respectively.
- (7) Sony Group Corporation is interested in approximately 33.95% of the shares of M3, Inc.. Sony Group Corporation is deemed to be interested in the 267,540,000 Shares held by M3, Inc.. Sony Group Corporation is the largest shareholder and an affiliate of M3, Inc..
- (8) FIL Limited, through corporations controlled by it, is interested in 64,986,433 Shares. Pandanus Partners L.P. has 38.71% control over FIL Limited and Pandanus Associates Inc. has 100% control over Pandanus Partners L.P.. Hence, Pandanus Partners L.P. and Pandanus Associates Inc. are deemed to be interested in the 64,986,433 Shares in which FIL Limited has interests.
- (9) As at 30 June 2023, the total number of issued Shares was 720,334,000.

Save as disclosed above, as at 30 June 2023, the Directors were not aware of any other persons (other than the Directors or chief executive of the Company) who had any interests or short positions in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which would be recorded in the register required to be kept under Section 336 of the SFO.

附註：

- (1) 所有權益均為好倉。
- (2) 張曉峰先生為田立平女士之配偶。張曉峰先生視為於田立平女士持有權益的由 Tiantian Co., Limited 持有的 267,540,000 股股份中擁有權益，亦視為於由田立平女士持有的 2,891,000 股股份及可認購 7,603,500 股股份的首次公開發售前購股權中擁有權益。
- (3) 包括由張曉峰先生持有的 25,000 股股份及可認購 75,000 股股份的首次公開發售前購股權。
- (4) 劉領娣女士為田立新先生之配偶。劉領娣女士視為於田立新先生持有權益的由 Tiantian Co., Limited 持有的 267,540,000 股股份中擁有權益，亦視為於由田立新先生持有的 637,500 股股份及可認購 1,912,500 股股份的首次公開發售前購股權中擁有權益。
- (5) 包括由劉領娣女士持有的 25,000 股股份及可認購 75,000 股股份的首次公開發售前購股權。
- (6) Tiantian Co., Limited 分別由田立平女士、田立新先生及田立軍先生擁有 48%、37% 及 15% 權益。
- (7) Sony Group Corporation 擁有 M3, Inc. 約 33.95% 股份權益。Sony Group Corporation 被視為於 M3, Inc. 所持 267,540,000 股股份擁有權益。Sony Group Corporation 是 M3, Inc. 的最大股東及聯屬公司。
- (8) FIL Limited 透過其控制的法團擁有 64,986,433 股股份的權益。Pandanus Partners L.P. 擁有 FIL Limited 38.71% 的控制權而 Pandanus Associates Inc. 擁有 Pandanus Partners L.P. 100% 的控制權。因此 Pandanus Partners L.P. 及 Pandanus Associates Inc. 被視為於 FIL Limited 擁有權益的 64,986,433 股股份擁有權益。
- (9) 於 2023 年 6 月 30 日，已發行股份總數為 720,334,000 股股份。

除上文所披露者外，於 2023 年 6 月 30 日，就董事所知，概無任何其他人士（董事及本公司最高行政人員除外）於股份或相關股份中擁有根據《證券及期貨條例》第 XV 部第 2 及 3 分部須向本公司披露的權益或淡倉，或須登記在根據《證券及期貨條例》第 336 條規定設立的登記冊的權益或淡倉。

Other Information 其他資料

SHARE OPTION SCHEMES

Pre-IPO Share Option Scheme

On 29 March 2021, the Company adopted the pre-IPO share option scheme (the “**Pre-IPO Share Option Scheme**”). The Pre-IPO Share Option Scheme is intended to provide employees of the Group with an opportunity to enjoy its success and incentives to their future performance. On 2 April 2021, the Pre-IPO Share Options representing 26,754,000 underlying Shares, representing approximately 3.71% of the Company’s current issued share capital were granted. The exercise price of the Pre-IPO Share Options is RMB0.38 per Share. The Pre-IPO Share Options shall be vested in four equal tranches with the vesting date on the first, second, third and fourth anniversary date of the Company’s listing, being 15 July 2021. No further options may be granted under the Pre-IPO Share Option Scheme after the Company’s listing. The Pre-IPO Share Option Scheme shall terminate upon the fifth anniversary date of the Company’s listing.

Further details of the principal terms of the Pre-IPO Share Option Scheme are set out in the 2022 Annual Report.

Particulars of the outstanding share options granted under the Pre-IPO Share Option Scheme as at 30 June 2023 are set out below:

Name/Category of grantees	Date of grant	No. of Shares involved in outstanding share options				Cancelled during the Reporting Period	Lapsed during the Reporting Period	No. of Shares involved in outstanding Share Options		Exercise price (RMB per Share)	Exercise period ⁽¹⁾	Weighted average closing price of the shares immediately before exercise dates
		as at 1 January 2023	Granted during the Reporting Period	Exercised during the Reporting Period	Exercised during the Reporting Period			as at 30 June 2023	Exercise price (RMB per Share)			
承授人姓名/類別	授出日期	於2023年1月1日未行使購股權所涉股份數目	報告期內授出	報告期內行使	報告期內註銷	報告期內失效	6月30日未行使購股權所涉股份數目	行使價(每股人民幣)	行使期 ⁽¹⁾	緊接於行使日期前之股份加權平均收市價		
Tian Liping (Chairwoman, Chief Executive Officer and executive Director)	2 April 2021	9,428,000	-	1,824,500	-	-	7,603,500	0.38	15 July 2021 to 15 July 2026	10.02		
田立平(董事長、首席執行官兼執行董事)	2021年4月2日								2021年7月15日至2026年7月15日			
Tian Lixin (executive Director)	2 April 2021	2,090,000	-	177,500	-	-	1,912,500	0.38	15 July 2021 to 15 July 2026	9.69		
田立新(執行董事)	2021年4月2日								2021年7月15日至2026年7月15日			
Tian Lijun (executive Director)	2 April 2021	2,090,000	-	177,500	-	-	1,912,500	0.38	15 July 2021 to 15 July 2026	10.56		
田立軍(執行董事)	2021年4月2日								2021年7月15日至2026年7月15日			
Zhang Xiaoteng (spouse of Ms. Tian Liping)	2 April 2021	75,000	-	-	-	-	75,000	0.38	15 July 2021 to 15 July 2026	-		
張曉峰(田立平女士之配偶)	2021年4月2日								2021年7月15日至2026年7月15日			
Liu Lingdi (spouse of Mr. Tian Lixin)	2 April 2021	75,000	-	-	-	-	75,000	0.38	15 July 2021 to 15 July 2026	-		
劉領娣(田立新先生之配偶)	2021年4月2日								2021年7月15日至2026年7月15日			
Employees	2 April 2021	9,293,500	-	806,500	-	-	8,487,000	0.38	15 July 2021 to 15 July 2026	8.65		
僱員	2021年4月2日								2021年7月15日至2026年7月15日			
Total		23,051,500	-	2,986,000	-	-	20,065,500					

購股權計劃

首次公開發售前購股權計劃

於2021年3月29日，本公司已採納首次公開發售前購股權計劃(「**首次公開發售前購股權計劃**」)。首次公開發售前購股權計劃旨在給予本集團僱員機會享受本集團的成果並激勵僱員將來的表現。於2021年4月2日，已授出26,754,000股相關股份(相當於本公司現時已發行股本的約3.71%)的首次公開發售前購股權。首次公開發售前購股權的行使價為每股人民幣0.38元。首次公開發售前購股權須以四個等額批次歸屬，歸屬日期分別為上市日期(即2021年7月15日)後第一個、第二個、第三個及第四個週年。於本公司上市後，概無根據首次公開發售前購股權計劃授出其他購股權。首次公開發售前購股權計劃將於本公司上市後第五個週年時終止。

首次公開發售前購股權計劃主要條款的更多詳情載於2022年年報。

於2023年6月30日，根據首次公開發售前購股權計劃已授出而尚未行使的購股權詳情載列如下：

Notes:

- (1) The above share options shall be vested in four equal tranches with vesting date on 15 July 2022, 15 July 2023, 15 July 2024 and 15 July 2025.
- (2) The number of Shares issued pursuant to the share options exercised during the six months ended 30 June 2023 is 2,986,000, representing approximately 0.42% of the weighted average number of Shares in issue (being 717,912,514) during the six months ended 30 June 2023.

Post-IPO Share Option Scheme

On 18 June 2021, the Company adopted the post-IPO share option scheme (the “**Post-IPO Share Option Scheme**”) to incentivize and reward employees (whether full time or part-time) and directors of members of the Group or associated companies of the Company. No option has ever been granted under the Post-IPO Share Option Scheme. The Post-IPO Share Option Scheme has a term of 10 years and shall expire on the tenth anniversary of the Company’s listing, i.e. 15 July 2031.

Further details of the Post-IPO Share Option Scheme are set out in the 2022 Annual Report .

No options under the Post-IPO Share Option Scheme have been granted, exercised, cancelled or lapsed during the Reporting Period and there are no outstanding share options under the Post-IPO Share Option Scheme.

SHARE AWARD SCHEME

The Board adopted a share award scheme which took effect from 24 December 2021 (the “**Share Award Scheme**”). The main purpose of the Share Award Scheme is to encourage and retain selected personnel to work for the Group or to make contribution to the Group and to provide additional incentive for them to achieve performance goals, with a view to achieving the objective of increasing the value of the Company and aligning the interests of the selected personnel with the shareholders of the Company through ownership of Shares. The Share Award Scheme shall be valid and effective for a term of 10 years commencing on 24 December 2021, i.e. until 23 December 2031.

附註：

- (1) 上述購股權須以四個等額批次歸屬，歸屬日期分別為2022年7月15日、2023年7月15日、2024年7月15日及2025年7月15日。
- (2) 截至2023年6月30日止六個月根據已行使之購股權而發行股份數目為2,986,000股，佔截至2023年6月30日止六個月已發行股份加權平均數(即717,912,514股)約0.42%。

首次公開發售後購股權計劃

於2021年6月18日，本公司已採納首次公開發售後購股權計劃(「**首次公開發售後購股權計劃**」)以激勵和獎勵本集團成員公司或本公司聯營公司僱員(不論全職或兼職)及董事。概無根據首次公開發售後購股權計劃授出任何購股權。首次公開發售後購股權計劃為期十年，於本公司上市後第十個週年時(即2031年7月15日)屆滿。

首次公開發售後購股權計劃的更多詳情載於2022年年報。

報告期內，概無任何首次公開發售後購股權計劃項下之購股權獲授予、行使、註銷或失效，且沒有任何首次公開發售後購股權計劃項下尚未行使的購股權。

股份獎勵計劃

董事會已採納股份獎勵計劃，自2021年12月24日起生效(「**股份獎勵計劃**」)。股份獎勵計劃的主要目的是鼓勵及挽留為本集團工作或為本集團作出貢獻的特選人員，進一步激勵彼等達成業績目標，旨在提升本公司價值，讓特選人員透過持有股份擁有與本公司股東一致的利益。股份獎勵計劃有效期為自2021年12月24日起10年，即至2031年12月23日有效。

Other Information 其他資料

On 17 January 2022, the Company appointed Futu Trustee Limited as an independent trustee for the purpose of the Share Award Scheme. Futu Trustee Limited is a trust company registered under section 78(1) of the Trustee Ordinance (Chapter 29 of the Laws of Hong Kong). It is a third party independent of and not connected with the Company and/or any of its connected persons.

No Share Awards were granted, exercised, cancelled or lapsed during the Reporting Period.

Particulars of the outstanding share awards granted under the Share Award Scheme as at 30 June 2023 are set out below:

Category of grantees	Date of grant	No. of Shares involved in outstanding share awards as at 1 January 2023			Cancelled during the Reporting Period	Lapsed during the Reporting Period	No. of Shares involved in outstanding share awards as at 30 June 2023			Exercise price (RMB per Share)	Exercise period ⁽²⁾
		Granted during the Reporting Period	Exercised during the Reporting Period	Exercised during the Reporting Period			Granted during the Reporting Period	Exercised during the Reporting Period	Exercised during the Reporting Period		
承授人類別	授出日期	於2023年1月1日未行使股份獎勵所涉股份數目	報告期內授出	報告期內行使	報告期內註銷	報告期內失效	於2023年6月30日未行使股份獎勵所涉股份數目	行使價	行使期 ⁽²⁾		
Employee 僱員	17 January 2022 2022年1月17日	500,000	-	-	-	-	500,000	- ⁽¹⁾	19 July 2023 to 19 July 2030 2023年7月19日至2030年7月19日		

Notes:

- The grantee paid US\$0.00001 per share award upon acceptance of the 500,000 share awards. No further consideration is payable by the grantee upon vesting.
- The share awards shall be vested in eight equal tranches with the vesting date on 19 July of each year beginning in 2023 and ending in 2030.

As at 1 January 2023 and 30 June 2023, (i) the total number of share awards and share options available for grant under the Share Award Scheme and the Post-IPO Share Option Scheme is 69,017,600; and (ii) the total number of Shares which may be issued pursuant to share awards or options granted or to be granted under the Share Award Scheme and the Post-IPO Share Option Scheme is 69,017,600, representing approximately 9.58% of the issued share capital of the Company as at 30 June 2023.

2022年1月17日，本公司就股份獎勵計劃委任富途信託有限公司為獨立受託人。富途信託有限公司為根據香港法例第29章《受託人條例》第78(1)條註冊的信託公司，為獨立第三方，與本公司及／或其任何關連人士並無關連。

於報告期內，概無股份獎勵獲授予、行使、註銷或失效。

於2023年6月30日根據股份獎勵計劃授出的未行使股份獎勵詳情載列如下：

附註：

- 承授人於接納500,000份股份獎勵時就每份股份獎勵支付0.00001美元。承授人於歸屬時無須支付其他代價。
- 股份獎勵將以八個等額批次歸屬，歸屬日期分別為2023年至2030年各年7月19日。

於2023年1月1日及2023年6月30日，(i) 根據股份獎勵計劃及首次公開發售後購股權計劃可予授出之股份獎勵及購股權總數為69,017,600股；及(ii)根據股份獎勵計劃及首次公開發售後購股權計劃授出或將授出的股份獎勵或購股權而可能發行的股份總數為69,017,600股，佔本公司於2023年6月30日已發行股本約9.58%。

PURCHASES, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any listed securities of the Company during the Reporting Period.

INTERIM DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS

The Board has resolved to declare an interim dividend of RMB0.1067 (equivalent to HK\$0.1165 based on the rate of HK\$1.0917 to RMB1.00, being the official exchange rate of HK dollars against Renminbi as quoted by the People's Bank of China on 28 August 2023) per Share. The interim dividend will be paid in Hong Kong dollars at HK\$0.1165 per Share. The interim dividend will be paid on or around 4 December 2023 to shareholders whose names appear on the register of members of the Company on 13 November 2023. The register of members of the Company will be closed from 9 November 2023 to 13 November 2023 (both days inclusive), for the purpose of determining shareholders' entitlements to the interim dividend. In order to qualify for the interim dividend, all transfer documents, accompanied by relevant share certificates, must be lodged for registration with the Company's Hong Kong share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on 8 November 2023.

Going forward, the Company will continue to formulate its dividend plan in light of its operation needs, earnings, financial condition, working capital requirements and future business plans, market conditions affecting the Company and other factors as the Board may deem relevant at such time.

購買、出售或贖回本公司上市證券

報告期間本公司或其任何附屬公司概無購買、出售或贖回任何本公司上市證券。

中期股息及暫停辦理股份過戶登記手續

董事會決議宣派中期股息每股股份人民幣0.1067元(按照中國人民銀行於2023年8月28日所報的港元兌人民幣官方匯率1.0917港元兌人民幣1.00元,相當於0.1165港元)。中期股息將以港元派付,每股0.1165港元。本公司將於2023年12月4日或前後,向於2023年11月13日名列本公司股東名冊的股東派發中期股息。為確定有權享有中期股息的股東資格,本公司將於2023年11月9日至2023年11月13日(包括首尾兩日)暫停辦理股份過戶登記手續。為合資格享有中期股息,所有股份過戶文件連同有關股票須於2023年11月8日下午四時三十分前送抵本公司香港股份過戶登記處卓佳證券登記有限公司辦理登記,地址為香港夏慤道16號遠東金融中心17樓。

未來本公司將繼續根據其運營需要、收益、財務狀況、營運資金要求和未來業務計劃、影響本公司的市場狀況以及董事會當時可能認為相關的其他因素,釐定本公司的股息計劃

Other Information 其他資料

CONTRACTUAL ARRANGEMENTS

The Group is primarily engaged in the operation of an online professional physician platform and mainly offers three types of solutions, namely precision marketing and corporate solutions, medical knowledge solutions and intelligent patient management solutions. The provision of medical knowledge solutions on the Group's *Medlive* website and desktop and mobile applications involves the provision of medical information and content for fees (including membership fees) and therefore is subject to restrictions under PRC regulations relating to value-added telecommunication. Furthermore, the Group is also engaged in the business of foreign-related market investigation as well as the production of radio and television video and programs and Internet culture business. The provision of Internet hospital services, data processing and storage support services as well as the operation of software as a service or SaaS solution platform for academic conferences may also be subject to foreign ownership restrictions. As such, the Group is restricted from holding direct interests in:

- (i) Beijing Yimaihutong Technology Co., Ltd. (北京醫脈互通科技有限公司) (“**Yimaihutong**”) which holds a licence for provision of Internet information services (the “**ICP Licence**”), a radio and television program production licence (the “**Radio and TV Licence**”) and an Internet cultural operation licence (the “**Internet Culture Licence**”) as well as a licence for foreign-related investigation;
- (ii) Yinchuan Yimaitong Internet Hospital Co., Ltd. (銀川醫脈互通互聯網醫院有限公司), a wholly-owned subsidiary of Yimaihutong, which holds a medical institution practicing licence to engage in the provision of Internet hospital service;
- (iii) Shanghai Yimaitong Huilin Medical Technology Co., Ltd. (上海醫脈通匯臨醫藥科技有限公司), a 60% subsidiary of Yimaihutong; and
- (iv) Beijing Medcon Information Consulting Co., Ltd. (北京美迪康信息諮詢有限公司), a 60% subsidiary of Yimaihutong, which holds an ICP Licence, a Radio and TV Licence and an Internet Culture Licence.

合約安排

本集團主要經營線上專業醫師平台，主要提供三類解決方案，即精準營銷及企業解決方案、醫學知識解決方案及智能患者管理解決方案。在本集團醫脈通網站以及桌面應用程式與移動應用程式提供醫學知識解決方案涉及提供收費(包括會員費)的醫學知識及內容，因此須遵守有關增值電信服務的中國法規。此外，本集團亦從事涉外市場調查及廣播及電視視頻與節目製作和網絡文化業務。提供互聯網醫院服務、數據處理和存儲支持服務以及經營學術會議SaaS(即軟件作為服務)解決方案平台為限制外商投資的產業。因此，本集團受限於直接持有：

- (i) 北京醫脈互通科技有限公司(「醫脈互通」)(其持有電信與信息服務業務經營許可證(「ICP許可證」)、廣播電視節目製作許可證(「廣播電視許可證」)、網絡文化經營許可證(「網絡文化經營許可證」)及涉外調查許可證)；
- (ii) 醫脈互通全資附屬公司銀川醫脈互通互聯網醫院有限公司(其持有經營互聯網醫院服務所需的醫療機構執業許可證)；
- (iii) 醫脈互通持有60%的附屬公司上海醫脈通匯臨醫藥科技有限公司；及
- (iv) 醫脈互通持有60%的附屬公司北京美迪康信息諮詢有限公司(其持有ICP許可證、廣播電視許可證及網絡文化經營許可證)的股權。

In order to comply with PRC laws and regulations while maintaining effective control over all of the Group's operations, the Company has, through its indirectly wholly-owned subsidiary, Kingyee (Beijing), entered into a series of contractual arrangements with Yimaihutong and its shareholders, Ms. Tian Liping and Mr. Tian Lixin, to exercise effective control over the operations and substantially all of the economic benefits of Yimaihutong and its subsidiaries. Mr. Tian Lixin acquired 50% equity interest in Yimaihutong from Dr. Li Zhuolin in April 2023. For details of the contractual arrangements, please refer to the Company's announcement dated 14 April 2023 and the section headed "Continuing Connected Transactions – A. Contractual Arrangements" in the Report of Directors included in the 2022 Annual Report.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

During the Reporting Period, the Company has complied with the applicable code provisions as set forth in Part 2 of the Corporate Governance Code contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") (the "Corporate Governance Code"), except for a deviation from code provision C.2.1 which requires that the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Ms. Tian Liping ("Ms. Tian") is the chairwoman and chief executive officer of the Company. With extensive experience in the medical information technology industry, Ms. Tian is responsible for formulating and implementing the overall development strategies and business plans of the Group and oversees the overall development and operations of the Group. Ms. Tian founded the Group in 1996 and is instrumental to the Company's growth and business expansion since its establishment. The Board considers that vesting the roles of chairwoman and chief executive officer in the same person is beneficial to the management of the Group. The balance of power and authority is ensured by the operation of the senior management and the Board, which comprises experienced and high-calibre individuals. The Board currently comprises four executive Directors (including Ms. Tian), two non-executive Directors and three independent non-executive Directors and therefore, in the Company's view, has an appropriate level of independence element in its composition.

為符合中國法律及法規，同時保持對本集團所有業務的有效控制，本公司已透過其間接全資附屬公司金葉天成北京與醫脈互通及其股東田立平女士及田立新先生訂立一系列合約安排，以對醫脈互通及其附屬公司的營運行使實際控制權及獲得醫脈互通及其附屬公司的絕大部分經濟利益。田立新先生於2023年4月從李卓霖博士購入醫脈互通50%股本權益。有關合約安排的詳情，請參閱本公司日期為2023年4月14日之公告及包含在2022年年報內的董事會報告中的「持續關連交易 – A.合約安排」一節。

遵守企業管治守則

於報告期間，本公司已遵守《香港聯合交易所有限公司證券上市規則》(《上市規則》)附錄十四所載企業管治守則(《企業管治守則》)第二部份載列的適用守則條文，惟偏離守則條文第C.2.1條除外，該條規定董事長及首席執行官的職務須予區分，不可由同一人擔任。

田立平女士(「田女士」)為本公司董事長兼首席執行官。田女士擁有豐富的醫學信息技術行業經驗，負責制定及實施本集團整體發展戰略及業務計劃，以及監督本集團的整體發展及營運。田女士於1996年成立本集團，自成立以來對本公司的增長及業務擴充至關重要。董事會認為由同一人擔任董事長及首席執行官有利於本集團管理。高級管理層及董事會由經驗豐富而能幹的人才組成，在營運過程中會確保權力及權限的平衡。董事會當前由四名執行董事(包括田女士)、兩名非執行董事及三名獨立非執行董事組成，因此，本公司認為其在構成上具備適當獨立的元素。

Other Information 其他資料

The Board will continue to review and monitor the practices of the Company for the purpose of complying with the Corporate Governance Code and maintaining a high standard of corporate governance practices of the Company.

COMPLIANCE WITH MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code as set out in Appendix 10 to the Listing Rules as its code of conduct regarding directors' securities transactions. All Directors have confirmed, following specific enquiry by the Company, that they have complied with the Model Code during the Reporting Period.

AUDIT COMMITTEE

The Company has established the Audit Committee (the “**Audit Committee**”) with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code. As at the date of this interim report, the Audit Committee comprises three independent non-executive Directors, namely, Ms. Wang Shan, Mr. Richard Yeh and Dr. Ma Jun. Ms. Wang Shan is the chairwoman of the Audit Committee.

The Audit Committee has reviewed the Company's unaudited consolidated interim results and interim report for the Reporting Period, and confirms that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made.

CHANGE IN DIRECTORS' BIOGRAPHICAL DETAILS UNDER RULE 13.51B(1) OF THE LISTING RULES

Dr. Li Zhuolin resigned as a non-executive Director with effect from 14 April 2023.

Mr. Kazutaka Kanairo has been appointed as a non-executive Director with effect from 14 April 2023.

Mr. Richard Yeh was appointed as an independent non-executive director of ADICON Holdings Limited with effect from 24 June 2021. ADICON Holdings Limited (stock code: 9860) became a Hong Kong listed company on 30 June 2023.

Save as disclosed above, there has been no change in the Directors' biographical details which are required to be disclosed pursuant to rule 13.51B(1) of the Listing Rules.

董事會將持續檢討及監督本公司的常規，以遵守企業管治守則及維持本公司的高水平企業管治常規。

董事遵守進行證券交易的標準守則

本公司已採納《上市規則》附錄十所載標準守則，作為董事進行證券交易的行為守則。經本公司作出具體查詢，所有董事已確認，於報告期間彼等均已遵守標準守則。

審核委員會

本公司已成立審核委員會（「**審核委員會**」），書面職權範圍乃遵照《上市規則》第3.21條及企業管治守則制訂。於本中期報告日期，審核委員會包括三名獨立非執行董事，即王珊女士、葉霖先生及馬軍醫師。王珊女士為審核委員會主席。

審核委員會已審閱本公司報告期間的未經審核綜合中期業績及中期報告，並確認已遵守適用會計原則、準則及規定以及已作出充分披露。

《上市規則》第13.51B(1)條項下董事履歷詳情變動

李卓霖博士辭任非執行董事，自2023年4月14日生效。

金色一賢先生獲委任為非執行董事，自2023年4月14日生效。

葉霖先生自2021年6月24日獲委任為艾迪康控股有限公司之獨立非執行董事。艾迪康控股有限公司(股份代號：9860)於2023年6月30日成為香港上市公司。

除上文所披露者外，並無須根據《上市規則》第13.51B(1)條披露的董事履歷詳情變動。

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The shares of the Company were listed on the Stock Exchange on 15 July 2021. The net proceeds from the Company's global offering (including the exercise of the over-allotment option) was approximately HK\$4,677 million (the "IPO Proceeds"), which were to be utilized for the purposes as set out in the prospectus of the Company dated 30 June 2021 (the "Prospectus"). On 12 June 2023, the Company announced re-allocation of the use of the IPO Proceeds, the extension of timing of the use of the IPO Proceeds and the possible utilisation of idle IPO Proceeds to subscribe for or purchase wealth management products (the "Announcement"). For further details and reasons for such changes, please refer to the Announcement. The following table shows a summary of the allocation of the intended use of the IPO Proceeds as adjusted and set out in the Announcement, and the utilization as at 30 June 2023:

全球發售所得款項用途

本公司股份於2021年7月15日在聯交所上市。本公司全球發售所得款項淨額(包括行使超額配股權)約為4,677百萬港元(「首次公開發售所得款項」)，本將用於本公司日期為2021年6月30日之招股章程(「招股章程」)所載用途。於2023年6月12日，本公司宣佈了重新分配首次公開發售所得款項用途、延長首次公開發售所得款項動用時間以及可能動用閒置首次公開發售所得款項認購或購買理財產品(「公告」)。有關詳情及該等調整的原因，請參閱公告。下表載列首次公開發售所得款項擬定用途的分配(如公告所載經調整)及截至2023年6月30日的動用情況概要：

Intended use of IPO Proceeds	Allocation of intended use of IPO Proceeds (as adjusted) 首次公開發售所得款項擬定用途分配(經調整) (HK\$ millions) (百萬港元)	Utilization as at 30 June 2023 截至2023年6月30日已動用金額 (HK\$ millions) (百萬港元)	Remaining balance as at 30 June 2023 截至2023年6月30日的餘額 (HK\$ millions) (百萬港元)	Expected time of use 預計動用時間
A. Business Expansion 業務擴展				
(1) enhance medical knowledge solutions of the Company and enrich medical knowledge information and tools on the platform of the Company 改進本公司的醫學知識解決方案，並豐富本公司平台的醫學知識信息及工具	280.7	26.3	254.4	before December 2027 2027年12月前
(2) improve patient care offerings 提升患者護理服務	187.1	5.1	182.0	before December 2027 2027年12月前
(3) strengthen intelligent clinical research solutions 改進智能臨床科研解決方案	140.3	6.0	134.3	before December 2027 2027年12月前
(4) strengthen the relationships with the existing customers of the Company and develop and attract additional customers in pharmaceutical, biotechnology and medical device industries 鞏固本公司與現有客戶的關係，開發及吸引更多製藥、生物技術及醫療設備行業的客戶	187.1	40.9	146.2	before December 2027 2027年12月前
(5) enhance user growth and engagement through targeted sales and marketing activities 通過針對性銷售及市場營銷活動，促進用戶增長與參與	140.3	24.8	115.5	before December 2027 2027年12月前

Other Information 其他資料

Intended use of IPO Proceeds	Allocation of intended use of IPO Proceeds (as adjusted) 首次公開發售所得款項擬定用途分配(經調整) (HK\$ millions) (百萬港元)	Utilization as at 30 June 2023 截至2023年6月30日已動用金額 (HK\$ millions) (百萬港元)	Remaining balance as at 30 June 2023 截至2023年6月30日的餘額 (HK\$ millions) (百萬港元)	Expected time of use 預計動用時間
B. Investment in technology and enhancement of research and development capabilities 投資技術及提高研發能力				
(1) recruit talent and collaborate with experts 招聘人才及與專家合作	467.7	77.2	390.5	before December 2027 2027年12月前
(2) develop and expand the application scenarios of technology of the Company, particularly, machine learning, natural language processing, knowledge graph and user understanding 開發及擴展本公司技術的應用情景，尤其是機器學習、自然語言處理、知識圖譜及用戶理解	374.2	14.9	359.3	before December 2027 2027年12月前
(3) build up the data center of the Company and strengthen the computing power and storage capabilities of the IT infrastructure of the Company 建立本公司的數據中心及提高本公司IT基礎設施的計算能力及存儲能力	93.6	9.2	84.4	before December 2027 2027年12月前
C. Pursue strategic investments or acquisitions opportunities 把握戰略投資或收購機會				
	2,338.6	177.1	2,161.5	N/A 不適用
D. General replenishment of the working capital of the Company and for other general corporate purposes 補充本公司一般營運資金及其他一般企業用途				
	467.7	105.0	362.7	N/A 不適用
Total 總計	4,677.3	486.5	4,190.8	

As at 30 June 2023, unutilised IPO Proceeds were deposited with licensed financial institutions and no IPO Proceeds have been used for the subscription or purchase of wealth management products.

於2023年6月30日，未動用之首次公開發售所得款項已存入持牌金融機構，且並無首次公開發售所得款項用於認購或購買理財產品。

EVENTS AFTER THE REPORTING PERIOD

There was no important event affecting the Group which occurred after the end of the Reporting Period up to the date of this interim report.

報告期後事項

報告期末後直至本中期報告日期，概無發生影響本集團的重大事項。

